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ABSTRACT
Overactive bladder (OAB) is a pervasive and debilitating condition for which  
effective therapeutic modalities are lacking. As potential novel pharmacological targets for 
lower urinary tract dysfunction, our recent studies have demonstrated voltage-gated KV7 
channels (KV7.1-KV7.5) to be functionally expressed in detrusor smooth muscle (DSM) of 
the urinary bladder. Nonetheless, the specific roles of individual KV7 channel subtypes 
remains poorly understood. Using Western blot, immunocytochemistry, isometric DSM 
tension recordings, ratiometric fluorescence Ca2+ imaging, and patch-clamp 
electrophysiology, we demonstrated expression and key physiologic roles for the 
KV7.2/KV7.3 channels in guinea pig DSM using the novel and selective KV7.2/KV7.3 
channel opener N-(2-Chloro-5-pyrimidinyl)-3,4-difluorobenzamide (ICA-069673). We 
further sought to pharmacologically target KV7.4- and KV7.5-containing channels, which 
evidence suggests are the prominent subtypes expressed in smooth muscle, to determine 
their involvement in regulating DSM excitation-contraction coupling. The novel 
KV7.4/KV7.5 channel activator N-(2,4,6-Trimethylphenyl)-bicyclo[2.2.1]heptane-2-
carboxamide (ML213) was shown to enhance KV7 channel currents in isolated DSM cells, 
hyperpolarize the DSM cell membrane potential, and attenuate the contractile activity of 
DSM isolated strips via a Ca2+-dependent mechanism. ML213 exhibited significantly 
greater potency for inhibition of DSM contractility in comparison to KV7.2/KV7.3 channel 
opener ICA-069673. Using in situ proximity ligation assay  
(PLA), it was further revealed KV7.4 and KV7.5 channel α-subunits co-localize to form
vi 
heteromeric KV7.4/KV7.5 channel complexes in DSM isolated cells. These studies suggest  
KV7.4/KV7.5 channels are functionally expressed in guinea pig DSM, where they critically  
regulate DSM excitability and contractility.  
Finally, to ascertain the translational implications of our aforementioned findings 
from experimental animals, we examined KV7 channel expression and function in human 
DSM. KV7 channel activators and inhibitors were shown to attenuate and potentiate, 
respectively, human DSM excitability and contractility in normal and OAB samples. 
Noteworthy, using in situ PLA, we confirmed the molecular interaction between KV7.4 and 
KV7.5 channel α-subunits, suggesting heteromeric KV7.4/KV7.5 channel subtype 
expression at the cellular level in human DSM cells. These findings are consistent with our 
findings in guinea pig  
DSM and provide strong support to suggest KV7.4/KV7.5 channels are among the key  
subtypes regulating human DSM function.  
In conclusion, our combined studies reveal  
novel insights into the expression, subunit composition, and physiological roles of KV7  
channel in DSM, providing critical information for directing future research efforts  
concerning the utility of KV7 channels as therapeutic targets for OAB.
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Urinary Bladder Structure, Function, and Regulation 
The urinary bladder facilitates two major functions: the storage and voiding of 
urine. Under physiological conditions, parasympathetic nerves release ACh and ATP to 
activate muscarinic ACh receptors (mAChRs) and purinergic receptors, respectively, to 
trigger bladder contraction and micturition (i.e. urine voiding)[1-3]. Within the walls of the 
urinary bladder detrusor smooth muscle (DSM), the main muscular component of the 
bladder, facilitates bladder contraction in response to mAChR activation. In human DSM, 
ACh-induced activation of mAChRs constitutes the primary mechanism initiating bladder 
contraction in urine voiding [1]. In addition to these nerve-mediated mechanisms, human 
DSM also exhibits spontaneous action potentials, intrinsic activity of the DSM cells which 
underlies the spontaneous phasic contractility of the bladder. 
DSM contractility is mainly dependent upon an increase in global intracellular Ca2+ 
concentrations ([Ca2+]i) as the rise in [Ca
2+]i leads to the activation of myosin-light chain 
kinase pathways which underlies smooth muscle contractility (23, 44). As exemplified by 
Figure 1.2, ACh-induced activation of mAChRs can increases global intracellular Ca2+ 
concentrations via phospholipase C-mediated activation of sarcoplasmic reticulum IP3 
receptors, which results in the release of Ca2+ from internal stores. Release of Ca2+ from 
the sarcoplasmic reticulum results in a dramatic increase in the local Ca2+ concentration, 
which can result in the activation of adjacent cation channels at the cell membrane. 
2 
Critically involved in the regulation of bladder contractility, K+ channels function to 
regulate Ca2+ entry through L-type voltage-gated Ca2+ (Cav) channels, and thus intracellular 
Ca2+ levels, by virtue of their influence upon the cell membrane potential[4]. While the 
etiology and pathophysiology of overactive bladder (OAB) is not fully known, it has been 
directly linked to DSM dysfunction. As such, the pivotal role of the K+ channels in 
controlling DSM cell membrane excitability has generated interest in their potential 
therapeutic utility for various forms of DSM dysfunction and OAB. 
 
1Figure 1.1 Schematic drawing of the bladder.  
                                                           
1 Reprinted from Andersson & Arner, 2004[1] with permission. 
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2Figure 1.2. Signal pathways (1–4) involved in activation of detrusor contraction via 
muscarinic M3 receptors. ACh, acetylcholine; PLC, phospholipase C; DAG, 
diacylglycerol; PKC, protein kinase C; MLC, myosin light chain; IP3, inositol 
trisphosphate; SR, sarcoplasmic reticulum; CIC, calcium-induced calcium release. There 
seem to be differences between species in the contribution of the different pathways in 
contractile activation. In human detrusor, Ca2+ influx (3) is of major importance.  
                                                           
2 Reprinted from Andersson & Arner, 2004[1] with permission. 
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Overactive bladder   
Overactive bladder (OAB) is currently among the most prevalent chronic health 
conditions in the United States with significant economic and health-related implications 
(47). As a syndrome, OAB is characterized by the lower urinary tract symptoms (LUTS) 
experienced by the individual, which includes urinary urgency, frequency, with or without 
urge urinary incontinence and nocturia (22). Despite the negative physical, social, and 
economic impact of OAB, evidence demonstrates this condition to have a detrimental 
impact upon individual’s mental health and quality of life by interfering with their sleep, 
work, and social interactions (33, 34). Affecting ~16.5% of the population, the increasing 
prevalence of OAB is expected to continue and by the year 2018, it will impact an estimated 
20.1% of the population at a cost of $82.6 billion (13, 27). However, these estimations 
underscore the widespread impact of OAB because as little as 25% of individuals affected 
actually pursue medical care (16).  
The primary treatment for OAB involves antimuscarinics (i.e. anticholinergics); 
however, these agents are not tissue- or organ-specific in their mechanism of action and 
thus give rise to bothersome side-effects including blurred vision, dry-mouth, and 
tachycardia (16, 19). This is evidenced by the current patient discontinuation rates of 80-
90% within the first year of treatment (18) with one report indicating the average time for 
patient discontinuation to be 31 days (15). More recently, a β3-adrenoceptor agonist known 
as mirabegron was approved by the FDA to treat OAB; however, its long-term efficacy is 
inconclusive (19). Likewise, intradetrusor botulinum toxin type A (OnabotulinumtoxinA) 
injections approved by the FDA in 2013 have shown to provide some effective 
symptomatic relief, yet this method of treatment is both invasive, requires IV sedation, and 
may call for recurrent injections to maintain clinical effectiveness (16). Therefore, the 
5 
considerable negative effects OAB has upon individual health, both physically and 
psychologically, dictates an urgent need for improved pharmacological therapeutics.  
The storage and periodical release of urine describes the two major functions of the 
urinary bladder (5), a process facilitated by the contraction and relaxation of urinary 
bladder smooth muscle (UBSM) (39). UBSM contractility is mainly dependent upon 
increased intracellular Ca2+ concentrations ([Ca2+]i) as the rise in [Ca
2+]i leads to the 
activation of myosin-light chain kinase pathways which underlies smooth muscle 
contractility (23, 44). Therefore, if the goal of OAB therapeutics is to promote UBSM 
relaxation, it is essential therefore to consider the key mechanisms controlling Ca2+ influx 
within human UBSM cells. This precisely defines the fundamental role of UBSM K+ 
channels, which by promoting cell membrane hyperpolarization, precludes Ca2+-influx 
through L-type (long-lasting) voltage-gated Ca2+ (Cav) channels to promote membrane 
hyperpolarization and thus UBSM relaxation (6, 9).  
Voltage-gated KV7 Channels 
Among all K+ channels, the voltage-gated KCNQ family has been shown to serve 
functional roles in rat, guinea pig (3,12 25) and human UBSM (26); however, among the 
40 genes encoding these channels, a subfamily of five channels encoded by KCNQ genes 
(KCNQ1-KCNQ5) have sparked great interest as potential pharmacological targets based 
on increasing evidence suggesting their involvement in a number of pathophysiological 
conditions including epilepsy, hypertension, chronic pain, and cardiac dysfunction (11, 20, 
35, 40). The KCNQ (or Kv7) channel family (KCNQ1-KCNQ5) attains vast heterogeneity 
as their five α subunits form distinct homo- or hetero-tetrameric complexes (see Figure 
1.3a) (42, 50). Further, KCNQ channels associate with KCNE-encoded β-regulatory 
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subunits (KCNE1-KCNE5), which may alter KCNQ channel biophysical properties 
including subcellular localization, pharmacology, and selectivity (1, 14, 30, 42, 48).  
The knowledge of KCNQ channel expression and function primarily arose from studies in 
the heart and brain, however physiological roles for KCNQ channels in other vascular and 
non-vascular tissues systems is now becoming more apparent (28, 29, 31, 32, 36, 43, 51). 
The important physiological roles KCNQ channels serve in various tissues has coincided 
with an increasing number of KCNQ channel pharmacological modulators, which has 
further heightened our understanding of these channels along with revealing some key 
distinctions between KCNQ channels and other smooth muscle K+ channels (30). 
Previously, the therapeutic utility of K+ channel pharmacological activators, specifically 
KATP channels activators, were unsuccessful due to concerns regarding drug 
selectivity[1]. However, this changed in 2011 with the FDA approval of the antiepileptic 
drug retigabine, which exerts its therapeutic effects by targeting KCNQ2-5 channels (21). 
This has led to retigabine being widely utilized throughout various tissues and animal 
models in order to elucidate KCNQ channel function in health and disease (30).  
Noteworthy and pertinent to this work, KCNQ channel functional roles, including 
in studies from our laboratory (2), have recently been identified within UBSM tissues of 
the guinea pig (2, 4), pig (46); and rat, where retigabine was shown to have pronounced 
effects in reducing UBSM contractility (41). This may elude to the increased micturition 
volume and voiding intervals observed in rats subjected to acute retigabine exposure in 
vivo (41, 45, 46).  More relevant, clinical evidence has proven retigabine to be associated 
with the increased occurrence of urinary retention (9). This indicates a potential role for 
KCNQ channel activity in regulating bladder function and therefore targeting these 
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channels may potentially provide beneficial relief for patients with OAB. While retigabine 
is a potent activator of KCNQ2-5 channels, the selectivity towards KCNQ2/3 channels is 
significantly greater than that of KCNQ4/5 as evidenced by experimentally determined 
EC50 values of 0.6 µM for KCNQ2/3 and 5.2-6.4 µM for KCNQ4/5 (21). KCNQ4 and 
KCNQ5 channel expression is predominate in smooth muscle (44) with KCNQ2/3 
channels important for neuronal function. This could be very significant as this may 
suggest the potential pharmacological efficacy of future selective KCNQ4/5 channel 
activators as effective treatments for OAB, while KCN2/3 selective modulators may prove 
better for the treatment of neurological conditions. Therefore, this may abolish the large 
number of adverse effects associated with current OAB treatments and thus the beneficial 
implications of this research is incredibly relevant to public health, clinical medicine, and 
most importantly, quality of life.  
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3Figure 1.3 Structure and function of K+ channels. (a) Planar membrane topologies of 
single potassium channel subunits for KV , BK Ca , and K ir channels, respectively. The 
pore-forming loop and the voltage sensor in transmembrane unit 4 are indicated. (b) 
Representative current traces recorded in human pulmonary arterial smooth muscle cells 
indicating diversity in the Kv currents; from left to right, (1) rapidly activating and slowly 
inactivating I K(V), (2) rapidly activating and noninactivating I K(V) , (3) slowly activating 
and noninactivating I K(V) , and (4) rapidly activating and rapidly inactivating I K(V)K.  
                                                           
3 Reprinted from Firth et al, 2011[5] with permission. 
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4Figure 1.4 Efferent pathways of the lower urinary tract 
a | Innervation of the female lower urinary tract. Sympathetic fibres (shown in blue) 
originate in the T11–L2 segments in the spinal cord and run through the inferior mesenteric 
ganglia (inferior mesenteric plexus, IMP) and the hypogastric nerve (HGN) or through the 
paravertebral chain to enter the pelvic nerves at the base of the bladder and the urethra. 
Parasympathetic preganglionic fibres (shown in green) arise from the S2–S4 spinal 
segments and travel in sacral roots and pelvic nerves (PEL) to ganglia in the pelvic plexus 
(PP) and in the bladder wall. This is where the postganglionic nerves that supply 
parasympathetic innervation to the bladder arise. Somatic motor nerves (shown in yellow) 
that supply the striated muscles of the external urethral sphincter arise from S2–S4 motor 
neurons and pass through the pudendal nerves. b | Efferent pathways and neurotransmitter 
mechanisms that regulate the lower urinary tract. Parasympathetic postganglionic axons in 
the pelvic nerve release acetylcholine (ACh), which produces a bladder contraction by 
stimulating M3 muscarinic receptors in the bladder smooth muscle. Sympathetic 
postganglionic neurons release noradrenaline (NA), which activates β3 adrenergic 
receptors to relax bladder smooth muscle and activates α1 adrenergic receptors to contract 
urethral smooth muscle. Somatic axons in the pudendal nerve also release ACh, which 
produces a contraction of the external sphincter striated muscle by activating nicotinic 
cholinergic receptors. Parasympathetic postganglionic nerves also release ATP, which 
excites bladder smooth muscle, and nitric oxide, which relaxes urethral smooth muscle (not 
shown). L1, first lumbar root; S1, first sacral root; SHP, superior hypogastric plexus; SN, 
sciatic nerve; T9, ninth thoracic root. Part amodified, with permission, from REF. 144 © (1996) 
W. B. Saunders Company. 
  
                                                           
4 Reprinted from Fowler et al., 2010[6] with permission. 
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CHAPTER 2  
EXPERIMENTAL APPROACH
Rationale and Central Hypothesis 
The important physiological role KV7 channels serve in smooth muscle tissues, which 
evidence shows to be subtype- and tissue-specific, suggests these channels may provide a 
novel platform for future OAB pharmacological treatments. The achievement of this will 
require an improved understanding of KV7 channel expression, subunit composition, and 
function in DSM excitability and contractility at both the single cell and whole-tissue level. 
The central hypothesis of these studies is that KV7 channels are critical regulators of 
human UBSM excitation-contraction coupling and thus KV7 channels provide a novel 




5Figure 1.5. Neural circuits that control continence and micturition 
a | Urine storage reflexes. During the storage of urine, distention of the bladder produces 
low-level vesical afferent firing. This in turn stimulates the sympathetic outflow in the 
hypogastric nerve to the bladder outlet (the bladder base and the urethra) and the pudendal 
outflow to the external urethral sphincter. These responses occur by spinal reflex pathways 
and represent guarding reflexes, which promote continence. Sympathetic firing also 
inhibits contraction of the detrusor muscle and modulates neurotransmission in bladder 
ganglia. A region in the rostral pons (the pontine storage centre) might increase striated 
urethral sphincter activity. b | Voiding reflexes. During the elimination of urine, intense 
bladder-afferent firing in the pelvic nerve activates spinobulbospinal reflex pathways 
(shown in blue) that pass through the pontine micturition centre. This stimulates the 
parasympathetic outflow to the bladder and to the urethral smooth muscle (shown in green) 
and inhibits the sympathetic and pudendal outflow to the urethral outlet (shown in red). 
Ascending afferent input from the spinal cord might pass through relay neurons in the 
periaqueductal grey (PAG) before reaching the pontine micturition centre. Note that these 
diagrams do not address the generation of conscious bladder sensations, nor the 
mechanisms that underlie the switch from storage to voiding, both of which presumably 
involve cerebral circuits above the PAG. R represents receptors on afferent nerve terminals.
 
                                                           
5 Reprinted from Fowler et al., 2010[6] with permission 
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CHAPTER 3
6THE NOVEL KV7.2/KV7.3 CHANNEL OPENER ICA-069673 REVEALS SUBTYPE-
SPECIFIC FUNCTIONAL ROLES IN GUINEA PIG DETRUSOR SMOOTH MUSCLE 
EXCITABILITY AND CONTRACTILITY 
 
ABSTRACT 
The physiological roles of voltage-gated KV7 channel subtypes (KV7.1-KV7.5) in 
detrusor smooth muscle (DSM) are poorly understood. Here, we sought to elucidate the 
functional roles of KV7.2/KV7.3 channels in guinea pig DSM excitability and contractility 
using the novel KV7.2/KV7.3 channel activator N-(2-chloro-pyrimidin-5-yl)-3,4-difluoro-
benzamide (ICA-069673). We employed a multi-level experimental approach using 
Western blot, immunocytochemistry with confocal microscopy, isometric DSM tension 
recordings, fluorescence Ca2+ imaging, and perforated whole cell patch-clamp 
electrophysiology. Western blot experiments revealed the protein expression of KV7.2 and 
KV7.3 channel subunits in DSM tissue. In isolated DSM cells, immunocytochemistry with 
confocal microscopy further confirmed protein expression for KV7.2 and KV7.3 channel 
subunits where they localize within the vicinity of the cell membrane. ICA-069673 
inhibited spontaneous phasic, pharmacologically-induced, and nerve-evoked contractions 
in DSM isolated strips in a concentration-dependent manner. The inhibitory effects of ICA-
069673 on DSM spontaneous phasic and tonic contractions were abolished in the presence 
                                                           
6 Provence, A., J. Malysz, and G.V. Petkov, The Novel KV7.2/KV7.3 Channel Opener ICA-069673 Reveals Subtype-Specific 
Functional Roles in Guinea Pig Detrusor Smooth Muscle Excitability and Contractility. The Journal of pharmacology and experimental 
therapeutics, 2015. 354(3): p. 290-301.  
Reprinted with permission of the American Society for Pharmacology and Experimental Therapeutics. All rights reserved 
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of the KV7 channel inhibitor XE991. Unlike nifedipine, under conditions of elevated 
extracellular K+ (60 mM), the effects of ICA-069673 on DSM tonic contractions were 
significantly attenuated. ICA-069673 decreased global intracellular Ca2+ concentration in 
DSM cells, and this effect was blocked by nifedipine. ICA-069673 hyperpolarized the 
membrane potential and inhibited DSM spontaneous action potentials of isolated DSM 
cells, effects which were blocked in the presence of XE991. In conclusion, the current 
study using the novel KV7.2/KV7.3 channel activator ICA-069673, provides strong 
evidence for a critical role for the KV7.2- and KV7.3-containing channels in DSM function 
at both cellular and tissue levels. 
INTRODUCTION 
Voltage-gated K+ (KV7) channels (KV7.1-KV7.5), also known as KCNQ (KCNQ1-
KCNQ5) channels, have recently been suggested as regulators of detrusor smooth muscle 
(DSM) excitability and contractility [7-9]. In DSM, the overall function of KV channels, 
which includes the KV7 channels, is to maintain and stabilize the resting membrane 
potential [4]. This is achieved by limiting the influx of Ca2+ through L-type voltage-gated 
Ca2+ (CaV) channels, which leads to DSM relaxation. The ability for DSM cells to generate 
spontaneous action potentials, which underlies DSM phasic contractility, allows this cell 
type to facilitate the function of the urinary bladder [4, 10, 11]. Under pathophysiological 
conditions such as overactive bladder (OAB), the contractile activity of DSM may be 
abnormally increased [12]. Thus, pharmacologically targeting bladder-specific KV7 
channel subtypes may represent a novel therapeutic strategy to control OAB. 
The KV7 channel family consists of five members (KV7.1-KV7.5), which form homomic or 
heteromeric tetramers of KV7 α-subunits. The diversity of KV7 channel combinations, such 
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as KV7.2/KV7.3 or KV7.3/KV7.5, expands their functional and biophysical properties [4, 
13, 14]. For example, heteromeric KV7.2/KV7.3 channels produce whole cell currents 10-
fold higher in amplitude than either homomeric KV7.2 or KV7.3 channels [14]. KV7 
channels can also associate with β-regulatory subunits (KCNE1-KCNE5), which may alter 
KV7 channel properties and subcellular localization [15, 16]. This diversity of KV7 
channels expression and function, underlie their attractiveness as potential novel 
therapeutic targets for OAB. 
KV7 channel pharmacological modulators have proven useful for elucidating KV7 
channel functional roles in various tissues including vascular, bronchial, and 
gastrointestinal smooth muscle [17-24]. Such modulators include KV7 channel activators 
retigabine (KV7.2-KV7.5) and L-364,363 (KV7.1) as well as KV7 channel inhibitors XE991 
and linopiridine, which effectively block all KV7 channels. Potential KV7 channel 
functional role in DSM was suggested during the clinical trials of the antiepileptic drug 
retigabine. Patients undergoing treatment reported an increased occurrence of urinary 
retention compared to the placebo [25]. These findings correspond with in vivo studies in 
rodents, where retigabine increased bladder capacity while decreasing voiding frequency 
[26, 27]. 
In guinea pig DSM, mRNA transcripts for all KV7 channel subunits have been 
identified [8], with qPCR studies indicating that KV7.1, KV7.2, and KV7.5 channel α-
subunits are most prevalent in DSM cells [7]. KV7 channel inhibition with XE991 was 
associated with membrane depolarization and an increase in Ca2+ oscillations and phasic 
contractions in guinea pig DSM [7, 8]. KV7 channel activation with retigabine caused 
membrane hyperpolarization and inhibition of DSM phasic contractions [7]. KV7 channels 
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also regulate porcine DSM contractility, where the KV7.2 and KV7.4 channel activator 
ML213 displayed a comparable effect to retigabine in promoting DSM relaxation [28]. 
Despite emerging developments, KV7 channel subtype-specific physiological roles remain 
poorly understood due to the lack of selective pharmacological modulators capable of 
distinguishing among KV7 channel subtypes [29]. 
The novel compound N-2-chloro-5-pyrimidinyl-3,4-difluorobenzamide (ICA-
069673) was developed by Icagen, Inc. (Durham, NC) – now part of Pfizer as Neusentis – 
in a screening program to identify subtype-selective KV7 channel activators [30]. ICA-
069673 demonstrated 20-fold greater selectivity for heteromeric KV7.2/KV7.3 channels 
over KV7.3/KV7.5 with EC50 values of 0.69 µM and 14.3 µM, respectively [30]. ICA-
069673 did not affect KV7.1 channels, which are predominately expressed in the heart [30]. 
A recent study on A7r5 smooth muscle cell line demonstrated that ICA-069673 was 
effective in activating recombinantly expressed KV7.4 channels [31]. However, as KV7.4 
channel protein expression was not observed in guinea pig DSM [7], its functional 
relevance in DSM is unlikely. 
Here, we aimed to investigate the functional roles of KV7.2- and KV7.3-containing 
channels in DSM excitability and contractility by targeting them with the novel 
KV7.2/KV7.3 channel activator ICA-069673. We applied a multi-level experimental 
approach including immunocytochemistry with confocal microscopy, Western blot, 
isometric DSM tension recordings, Ca2+ imaging, and perforated whole cell patch-clamp 
electrophysiology to test the hypothesis that KV7.2- and KV7.3-containing channels are 
among the KV7 channel subtypes regulating DSM excitation-contraction coupling.  
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MATERIALS AND METHODS 
Ethical approval for animal use. Experimental procedures involving the use of animals, 
as described in this study, were reviewed and approved by the Institutional Animal Care 
and Use Committee (IACUC) of the University of South Carolina (Columbia, SC, USA), 
protocol #1747. 
Animal housing, euthanasia, and DSM tissue acquisition. A total of 38 adult male 
Hartley-Albino guinea pigs, ages ranging 3-12 months (Charles River Laboratories, 
Raleigh, NC, USA) and weights 310-575 g (average 463±16 g) were used in the present 
studies. Animals were housed at room temperature (22-23 ºC) within the Animal Resource 
Facilities at the University of South Carolina. Guinea pigs had free access to food and water 
and were exposed to 12 h light/dark cycles. Each animal was euthanized by CO2 inhalation 
using a SMARTBOX™ Automated CO2 Delivery System (Euthanex Corp, Palmer, PA, 
USA) followed by thoracotomy. The urinary bladder was subsequently removed by 
administering a transverse incision superior to the bladder neck.  
DSM single-cell isolation and collection. DSM single cells were enzymatically isolated 
using a combination of papain and collagenase as previously described [7]. DSM cells were 
used for Ca2+ imaging or electrophysiological experiments within 12 h after isolation. 
Intact DSM strips with urothelium removed were used for single cell isolation. 
Western blot analysis. Western blot experiments were performed according to previously 
described methods [10, 32]. For these experiments, the primary antibodies used were the 
anti-KCNQ2 (KV7.2) (1:200 dilution, Santa Cruz Biotechnology, Dallas, TX, USA, cat. 
number: sc-7793) or anti-KCNQ3 (KV7.3) (1:200 dilution, Santa Cruz Biotechnology, cat. 
number: sc-7794) polyclonal antibodies, respectively. The donkey anti-goat IgG-HRP 
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secondary antibody (1:500 dilution, Santa Cruz Biotechnology, cat. number: sc-2020) was 
used for all Western blot experiments. Experiments utilizing the competing peptides for 
KV7.2 (Santa Cruz Biotechnology, cat. number: sc-7793P) or KV7.3 (Santa Cruz 
Biotechnology, cat. number: sc-7794P) were pre-incubated with the KV7.2 or KV7.3 
primary antibodies, respectively. 
Immunocytochemistry. Immunocytochemical studies were conducted as previously 
described [10, 32]. Freshly-isolated DSM cells were incubated using either the anti-
KCNQ2 (KV7.2) primary antibody (1:300 dilution, Santa Cruz Biotechnology, cat. 
number: SC-7793), or the anti-KCNQ3 (KV7.3) primary antibody (1:300 dilution, Santa 
Cruz Biotechnology, cat. number: SC-7795-R) diluted in 1% BSA/PBS overnight at 4°C. 
DSM cells that were incubated with the anti-KV7.2 goat polyclonal antibody were then 
incubated with the secondary antibody Cy3-AffiniPure donkey anti-goat IgG (1:500 
dilution; cat. number: 705-165-147, Jackson ImmunoResearch Laboratories, Inc., West 
Grove, PA, USA) overnight at 4°C. DSM cells that were incubated with the anti-KV7.3 
rabbit polyclonal primary antibody were then incubated with the secondary antibody Cy5-
AffiniPure donkey anti-rabbit IgG (1:500 dilution; cat. number: 711-175-152, Jackson 
ImmunoResearch Laboratories, Inc.) overnight at 4°C. Subsequently, DSM cells were 
incubated in phosphate buffered saline (PBS) with the α-smooth muscle actin fluorescein 
isothiocyanate (FITC) antibody (cat. number: F3777, Sigma-Aldrich) for 2 h in a dark 
room. Nuclear staining was achieved by incubating DSM cells for 15 min in 4′,6-
diamidino-2-phenylindole (DAPI, Invitrogen, Ltd., Grand Island, NY, USA; diluted in 
PBS 1:10,000). DSM cells were mounted with 1,4-Diazabicyclo[2.2.2]octane (DABCO). 
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Confocal images were obtained with a 63x oil immersion objective using a laser scanning 
LSM 700 confocal microscope (Carl Zeiss, Germany). 
Isometric DSM tension recordings. Isometric DSM tension recordings were performed 
as previously described using DSM isolated strips free from urothelium [7, 10, 32, 33]. In 
urothelium-denuded DSM isolated strips showing spontaneous phasic contractions, the 
neuronal Na+ channel blocker tetrodotoxin (TTX, 1 µM) was included prior to the 
application of increasing concentrations of ICA-069673 (100 nM-30 µM). Two separate 
protocols were conducted involving electric field stimulation (EFS)-induced DSM 
contractions, which were performed in the absence of TTX using a PHM-152I 
programmable stimulator (Med Associates, Inc., Georgia, VT, USA). For the first protocol, 
continuous stimulation of 10 Hz EFS frequency was delivered at 1 min intervals and a 
stable baseline and amplitude were reached prior to applying increasing concentrations of 
ICA-069673 (100 nM-30 µM). In the second EFS protocol, we applied incremental EFS 
stimulation frequencies (3.5, 5, 7.5, 10, 12.5, 15, 20, 30, 40, 50 Hz) at 3 min intervals for 
a control period, and then again in the presence of a single concentration of ICA-069673 
(either 3 µM or 10 µM). 
Ratiometric fluorescence Ca2+ imaging in freshly-isolated guinea pig DSM cells. We 
measured the global intracellular Ca2+ levels of freshly-isolated DSM cells using fura-2 
AM, a ratiometric fluorescent Ca2+ probe, in accordance with previously described 
procedures [32]. 
Whole cell patch-clamp electrophysiology. Amphotericin-B perforated whole cell patch-
clamp experiments were performed in current-clamp mode as previously described [7, 32]. 
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All patch-clamp electrophysiological experiments were conducted at room temperature 
(22-23°C). 
Solutions and drugs. Ca2+-free dissection solution was composed of each of the following 
(in mM): 80 monosodium glutamate; 55 NaCl; 6 KCl; 10 glucose; 10 4-(2-
hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES); 2 MgCl2; NaOH was used to 
attain pH 7.3. PSS solution containing Ca2+ was freshly prepared each day and contained 
the following (in mM): 119 NaCl; 4.7 KCl; 24 NaHCO3; 1.2 KH2PO4; 2.5 CaCl2; 1.2 
MgSO4; 11 glucose; that was aerated with 95% O2/5% CO2 to attain pH 7.4. Physiological 
bath solution utilized for patch-clamp experiments was composed of the following (in 
mM): 134 NaCl; 6 KCl; 1 MgCl2; 2 CaCl2; 10 glucose; 10 HEPES; and NaOH was used 
to obtain pH 7.4. The patch-pipette solution contained (in mM): 110 potassium aspartate; 
30 KCl; 10 NaCl; 1 MgCl2; 10 HEPES; 0.05 ethylene glycol-bis(2-aminoethylether)-
N,N,N',N'-tetraacetic acid (EGTA); NaOH was used to adjust the pH to 7.2. Amphotericin-
B stock solution was freshly prepared daily in dimethyl sulfoxide (DMSO) and was 
included in the pipette solution (200-300 μg/ml) before the experiment and was 
subsequently replaced every 1-2 h. ICA-069673, XE991, fura-2 AM, and TTX were 
purchased from Tocris Bioscience (Minneapolis, MN) and were dissolved in DMSO, 
double distilled water, and acetate buffer at pH 4.8, respectively. Nifedipine was purchased 
from Sigma-Aldrich (St. Louis, MO, USA) and dissolved in DMSO. 
Data Analysis and Statistics. Isometric DSM tension recording experiments were 
conducted using MyoMed software and analyzed as previously described[7]. Data for 
isometric DSM tension were normalized and expressed in %. For spontaneous phasic, 
carbachol-induced, KCl-induced, and 10 Hz EFS-induced contractions, the 5 min period 
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preceding the first application of ICA-069673 (100 nM-30 µM) was taken as the control 
(100 %). Maximal efficacy values were normalized to the control, with 0% of the control 
indicating full inhibition. The effects of ICA-069673 (100 nM-30 µM) on DSM phasic 
contraction parameters were determined by analysis of the 5 min period preceding the 
subsequent addition of a higher concentration. In 3.5-50 Hz EFS-induced contractions, the 
control period was defined as the contraction amplitude observed at 50 Hz EFS frequency 
before the addition of ICA-069673 (3 or 10 µM) and taken as 100%. Perforated whole cell 
patch-clamp experiments were performed and analyzed using pCLAMP 10.2. When ICA-
069673 was applied in the presence of XE991, the control was defined as the 5 min period 
before the addition of ICA-069673 (in the presence of XE991 only). Where indicated in 
the summarized data, n represents the number of freshly-isolated DSM strips or cells, or 
individual immunocytochemistry/Western blot experiments, and N represents the number 
of guinea pigs. For spontaneous contraction experiments, statistical analysis for the 
comparison of ICA-069673 in the absence or presence of XE991, two-way ANOVA test 
was performed followed by Bonferroni post-hoc test. Remaining statistical analyses were 
performed using a two-tailed paired Students t-test. Summarized data are reported as 
means±SEM. P values <0.05 were considered statistically significant. Corel Draw Graphic 
Suite X3 software (Corel Co., Mountain View, CA) and GraphPad Prism 4.03 software 
(La Jolla, CA) was used for data illustration. 
RESULTS 
KV7.2- and KV7.3-containing channels are expressed in freshly-isolated DSM cells. To 
determine the protein expression of KV7.2 and KV7.3 channel subunits and their subcellular 
localization in DSM cells, we performed Western blot and immunocytochemical 
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experiments, respectively. Western blot data revealed the protein expression of KV7.2 and 
KV7.3 channel subunits in whole DSM tissue, which were not observed when the 
competing peptides for each KV7.2 and KV7.3 channel-specific antibodies were present 
(n=3, N=3, Figure 3.1). In freshly-isolated DSM cells, immunocytochemical experiments 
were conducted using antibodies specific for KV7.2 or KV7.3 channel subunits in 
combination with the α-smooth muscle actin-FITC antibody and DAPI nuclear stain 
(Figure 3.1). The data demonstrated that KV7.2 and KV7.3 channel subunits are expressed 
in DSM cells and localized within the vicinity of the cell membrane (n=3, N=3, Figure 
3.1). The detection of KV7.2 and KV7.3 channel protein expression in isolated DSM cells 
was abolished when the competing peptides for the KV7.2 or KV7.3 channel-specific 
antibodies were present (Figure 3.1). This confirms the specificity of the KV7.2 and KV7.3 
channel-specific antibodies used in this study. 
The Kv7.2/Kv7.3 chnanel activator ICA-069673 induces inhibition of spontanous 
phasic contrations in DSM isolated strips. In order to determine the functional roles of 
the KV7.2/KV7.3 channels on spontaneous phasic contractions in guinea pig DSM isolated 
strips, we conducted isometric DSM tension recordings using the novel KV7.2/KV7.3 novel 
activator ICA-069673. As shown in Figure 3.2, ICA-069673 (100 nM-30 µM) caused a 
concentration-dependent inhibition of spontaneous phasic contractions, an effect that 
recovered upon washout of ICA-069673. The IC50 and maximal efficacy values for ICA-
069673 on spontaneous phasic DSM contraction parameters were the following: 
contraction amplitude, 4.5 (2.6-7.9, 95% confidence interval) µM and 3.3±1.8% of pre-
compound control; muscle force integral, 3.2 (2.0-5.2) µM and 2.2±1.4%; contraction 
duration, 8.6 (4.3-17.3) µM and 9.8±5.2%, respectively. The IC50 value for the effect of 
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ICA-069673 on contraction frequency was 11.9 µM. The effect of ICA-069673 on 
contraction frequency resulted in maximal reduction of contraction frequency to 
25.2±14.1% of the control (n=11, N=7; P<0.05; Figure 3.2). To confirm that 
concentration-dependent inhibition of spontaneous phasic contractions caused by ICA-
069673 was mediated by KV7 channels, we examined its effects in the presence of the KV7 
channel inhibitor XE991 (10 µM). In the presence of XE991 (10 µM), there were no 
measureable inhibitory effects of ICA-069673 on DSM phasic contractions (n=12, N=6; 
P>0.05; Figure 3.2). These results support the concept that KV7.2- and KV7.3-containing 
channels are important physiologically-relevant mediators of spontaneous phasic 
contractions in DSM isolated strips. 
The Kv7.2/Kv7.3 chnanel activator ICA-069673 inhibits pharmacologically-induced 
contractions in DSM isolated strips. We examined the effects of ICA-069673 on DSM 
phasic contractions induced in response to either muscarinic receptor activation or 
sustained membrane potential depolarization using carbachol or KCl, respectively. ICA-
069673 (100 nM-30 µM) caused a concentration-dependent inhibition of 0.1 µM 
carbachol-induced DSM contractions. For 0.1 µM carbachol-induced contractions, the IC50 
and maximal efficacy values of ICA-069673 were: contraction amplitude, 5.5 (3.0-10.2, 
95% confidence interval) µM and 20.8±8.9%; muscle force integral, 3.6 (1.9-7.0) µM and 
18.9±8.2%; contraction duration, 13.3 (6.3-28.2) µM and 36.4±14.9%, respectively. DSM 
phasic contraction frequency was maximally reduced to a lesser extent to 46.5±18.2% of 
the control (n=10, N=7; P<0.05; Figure 3.3). ICA-069673 (100 nM-30 µM) concentration-
dependently inhibited DSM phasic contractions induced by 20 mM KCl. For 20 mM KCl-
induced contractions, the IC50 and maximal efficacy values for ICA-069673 on DSM 
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contraction parameters were as follows: contraction amplitude, 5.3 (2.6-11.0) µM and 
10.4±5.6%; and muscle force integral, 4.2 (2.4-7.6) µM and 5.3±3.6%; contraction 
duration, 11.1 (2.8-36.7) µM and 31.8±13.0%; and contraction frequency, 12.2 (3.4-44.2) 
µM and 22.5±8.9% of the control, respectively (n=7, N=7; P<0.05; Figure 3.4). We then 
tested the effects of ICA-069673 (10 μM) on DSM tonic contractions induced by 60 mM 
KCl to determine the role of K+ conductance in mediating the inhibitory effects of ICA-
069673 as well to assess the functional interaction with the L-type CaV channels. As 
illustrated in Figure 3.5, under these experimental conditions, ICA-069673 (10 µM) 
decreased DSM tone to only 89.2±3.2% of the control (n=8, N=4; P<0.05) while the 
subsequent addition of the L-type CaV channel inhibitor nifedipine (1 µM) led to a more 
significant reduction in DSM tone to 28.7±3.8% of the control (n=8-9, N=4; P<0.001; 
Figure 3.5). There was a statistically significant difference between the inhibitory effects 
of ICA-069673 and nifedipine on DSM tonic contraction (n=8-9, N=4; P<0.001). These 
experiments support the concept that ICA-069673 does not directly inhibit L-type CaV 
channels  
The Kv7.2/Kv7.3 chnanel activator ICA-069673 inhibits nerve-evoked contractions in 
DSM isolated strips. To assess the effects of ICA-069673 on nerve-evoked DSM 
contractions, we applied increasing concentrations of ICA-069673 to continuous 10 Hz 
EFS-induced contractions of DSM isolated strips. Under these experimental conditions, 
ICA-069673 (100 nM-30 µM) displayed a concentration-dependent inhibitory effect. For 
10 Hz EFS-induced contractions, the IC50 and maximal efficacy values for ICA-069673 on 
nerve-evoked DSM contraction parameters were as follows: contraction amplitude, 9.8 
(1.1-88.0) µM and 16.6±5.2%; and muscle force integral, 7.6 (0.6-97.8) µM and 19.0±5.4%   
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Figure 3.1. KV7.2 and KV7.3 channel subunits are expressed in freshly-isolated guinea 
pig DSM cells. Western blot analysis reveals the expression of (A) KV7.2 and (B) KV7.3 
channel subunits at the protein level in DSM (n=3, N=3). The expected molecular weights 
of KV7.2 and KV7.3 channel proteins are 120 and 97 kDa, respectively (indicated by the 
arrows). No protein expression was detected in the presence of the competing peptides 
(CP) for each KV7.2 and KV7.3 channel antibodies, respectively. Confocal images from 
immunocytochemical experiments demonstrate the expression KV7.2 (C) and KV7.3 (E) 
channel subunits in freshly-isolated DSM cells along with membrane localization. Red 
staining indicates detection of either KV7.2 or KV7.3 channel subunits. Blue staining 
depicts the nucleus. Cells stained with the α-smooth muscle actin-FITC antibody are shown 
in green. The overlaid image for KV7.2 or KV7.3 with α-smooth muscle actin-FITC 
antibody and DAPI nuclear stain is shown at the bottom right. Co-localization of KV7.2 or 
KV7.3 with the α-smooth muscle actin-FITC antibody is indicated by the yellow color in 
the merged images, respectively. Inclusion of competing peptides for either KV7.2 (D) or 
KV7.3 (E) channels resulted in loss of specific staining. Data for all experiments were 
confirmed using DSM tissues from at least 3 guinea pigs. Images were acquired with a 
Zeiss LSM 700 confocal microscope using a 63x oil objective.  
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Figure 3.2. ICA-069673 inhibits spontaneous phasic contractions in DSM isolated 
strips. A) An original isometric DSM tension recording illustrating the inhibition of 
spontaneous phasic contractions by ICA-069673 (100 nM-30 µM) in a DSM isolated strip. 
The DSM contractions recovered upon washout of ICA-069673. B) An original isometric 
DSM tension recording illustrating that blocking KV7 channels with its selective inhibitor 
XE991 (10 µM) abolished the inhibitory effects of ICA-069673 (100 nM-30 µM) on DSM 
spontaneous phasic contractions. C-F) Cumulative concentration-response curves for ICA-
069673 on DSM phasic contraction amplitude, muscle force, duration, and frequency in 
the absence or presence of 10 µM XE991 (see text for potency and maximum efficacy 
values). #P<0.05, ##P<0.01, and ###P<0.001 represent statistically significant effects of 
ICA-069673 on spontaneous phasic contractions in the absence of XE991 in comparison 
to the control level (i.e. 100%) prior to the addition of ICA-069673 (n=11, N=7). *P<0.05, 
**P<0.01, and ***P<0.001 represent statistically significant differences between the 
effects of ICA-069673 in the absence versus presence of XE991 (n=12, N=6).   
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Figure 3.3. ICA-069673 decreases carbachol-induced phasic contractions in DSM 
isolated strips. A) An original isometric DSM tension recording of 0.1 µM carbachol-
induced phasic contractions in a DSM isolated strip illustrating the concentration-
dependent inhibitory effects of ICA-069673 (100 nM-30 µM). B-E) Cumulative 
concentration-response curves for ICA-069673 (100 nM–30 µM) on DSM phasic 
contraction amplitude (B), muscle force (C), phasic contraction duration (D), and phasic 
contraction frequency (E) (n=10, N=7; *P<0.05, **P<0.01, and ***P<0.001); see text for 
potency and maximum efficacy values.  
 
of the control, respectively (n=9, N=9; P<0.05; Figure 3.6). Next, EFS-induced 
contractions were stimulated over a range of frequencies (3.5-50 Hz) in the absence or 
presence of either 3 or 10 μM ICA-069673, respectively. ICA-069673 (3 or 10 μM) 
significantly attenuated the amplitude of EFS-induced contractions stimulated at EFS   
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Figure 3.4. ICA-069673 decreases 20 mM KCl-induced phasic contractions in DSM 
isolated strips. A) An original isometric DSM tension recording illustrating the 
concentration-dependent inhibitory effects of ICA-069673 (100 nM-30 µM) on DSM 
phasic contractions induced by 20 mM KCl. B-E) Cumulative concentration-response 
curves for the effects of ICA-069673 on DSM phasic contraction amplitude (B), muscle 
force (C), phasic contraction duration (D), and phasic contraction frequency (E) (n=7, 
N=7; *P<0.05, **P<0.01, and ***P<0.001); see text for potency and maximum efficacy 
values. 
 
frequencies from 7.5-50 Hz (n=8-18, N=4-10; P<0.05; Figure 3.7). Collectively, these data 
support the concept that KV7.2- and KV7.3-containing channels are critical regulators of 
nerve-evoked DSM contractions. The Kv7.2/Kv7.3 chnanel activator ICA-069673 
decreases the global intracellular Ca2+ levels in freshly-isolated DSM cells. Next, we 
sought to determine the effects of ICA-069673 on global intracellular Ca2+ levels in DSM 
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Figure 3.5. Differential effects of ICA-069673 and nifedipine on 60 mM KCl 
depolarization-induced tonic contraction in DSM isolated strips. A) An original 
isometric DSM tension recording illustrating the effects of 10 µM ICA-069673 and 1 µM 
nifedipine on a depolarization-induced DSM tonic contraction caused by 60 mM KCl in a 
DSM isolated strip. B) Summarized data demonstrating the inhibitory effect of ICA-
069673 (10 µM) and nifedipine (1 µM) on DSM tonic contraction induced by 60 mM KCl 
(n=8-9, N=4; *P<0.05 and n=6-7, N=3; ***P<0.0001, respectively. ###P<0.0001 represents 
a statistically significant difference for the comparison of ICA-069673 and nifedpine. 
 
single cells by measuring the ratio of fura-2 AM fluorescent emission at 510 nm with 
excitation at 340 and 380 nm. For the control, the average emitted intensity (F340/F380) prior 
to ICA-069673 application was 0.470±0.006 (n=11, N=5). At 10 μM ICA-069673, there 
was a significant decrease in the F340/F380 ratio to 0.450±0.006 (n=11, N=5; P<0.05; Figure 
3.8). To elucidate the mechanism by which ICA-069673 regulates global intracellular Ca2+ 
concentrations, we studied the effects of ICA-069673 (10 µM) in the presence or absence 
of the L-type CaV channel blocker nifedipine (1 µM). In the presence of 1 µM nifedipine, 
ICA-069673 (10 µM) had no significant effect on intracellular Ca2+ levels, with the average 
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F340/F380 ratio being 0.470±0.008 compared to the control value of 0.480±0.005 (n=11, 
N=5; P>0.05; Figure 3.8). These results demonstrate that in guinea pig DSM cells, ICA-
069673 decreases global intracellular Ca2+ concentrations by an indirect mechanism 
involving inhibition of Ca2+ influx through L-type CaV channels, probably due to 
membrane hyperpolarization.  
ICA-069673 hyperpolarizes the resting membrane potential and inhibits spontaneous 
action potentials in freshly-isolated DSM cells. To determine the regulatory roles of 
KV7.2/KV7.3 channels on the DSM cell membrane potential, we employed the 
KV7.2/KV7.3 channel activator ICA-069673 and the perforated whole cell patch-clamp 
technique in current-clamp mode. The effect of ICA-069673 was examined in 7 DSM cells 
(N=6), which had mean cell capacitance of 43.4±4.3 pF and membrane potential of -
16.8±2.8 mV. Two of these seven DSM cells displayed distinguishable spontaneous action 
potentials. These spontaneous action potentials were abolished by ICA-069673 concurrent 
with membrane hyperpolarization (Figure 3.9). In all DSM cells, ICA-069673 
hyperpolarized the DSM cell membrane potential by 8.3±2.7 mV (n=7, N=6; P<0.05; 
Figure 3.9). The ICA-069673-mediated hyperpolarizing effects on the DSM cell 
membrane potential were fully reversible upon washout (Figure 3.9). We then examined 
the effects of the KV7 channel inhibitor XE991. As illustrated by the original recording in 
Figure 3.9 and summarized data in Figure 3.9, XE991 (10 µM) depolarized the DSM cell 
membrane potential by 4.9±1.4 mV (P<0.05; n=5, N=5). To further investigate the 
mechanism underlying ICA-069673-induced hyperpolarization, specifically its 
dependence on KV7 channel subtypes, the effect of this channel modulator 
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Figure 3.6. ICA-069673 decreases nerve-evoked contractions stimulated by 10 Hz 
EFS in DSM isolated strips. A) An original isometric DSM tension recording representing 
the concentration-dependent inhibitory effects of ICA-069673 (100 nM-30 µM) upon 
nerve-evoked contractions induced by 10 Hz EFS stimulation in a DSM isolated strip. B) 
Cumulative concentration-response curves for the effects of ICA-069673 (100 nM-30 µM) 
on DSM contraction (B) amplitude and (C) muscle force integral (n=9, N=9; **P<0.01, 
and ***P<0.001); see text for potency and maximum efficacy values. 
 
was examined in DSM cells pretreated with XE991 (10 µM). The subsequent addition of 
ICA-069673 in the continued presence of XE991 did not have a significant hyperpolarizing 
effect on the membrane potential of DSM cells (n=7, N=5; P>0.05; Figure 3.9). There was 
a statistically significant difference in the effects of ICA-069673 in the absence versus 
presence of XE991 (n=5-7, N=5-6; P<0.05; Figure 3.9). Collectively, these data supports 
the novel concept that KV7.2- and KV7.3-containing channels are key regulators of DSM 





Figure 3.7. ICA-069673 decreases 3.5-50 Hz EFS-induced contractions in DSM 
isolated strips. A-C) The original isometric DSM tension recordings of 3.5-50 Hz EFS-
induced contractions in DSM isolated strips A) before (control) and after the addition of 
B) 3 µM ICA-069673 and C) 10 µM ICA-069673. D-E) Cumulative concentration-
response curves demonstrating the effects of D) 3 µM ICA-069673 and E) 10 µM ICA-
069673 on the amplitude of 3.5-50 Hz EFS-induced contractions (n=8-18, N=4-10; 
*P<0.05, **P<0.01, and ***P<0.001).  
 
DISCUSSION 
The present study sought to elucidate the physiological roles of KV7.2- and KV7.3-
containing channels in DSM excitability and contractility by targeting their activity with 
the novel selective KV7.2/KV7.3 channel activator ICA-069673. This was achieved by 
applying a multi-level experimental approach at both cellular and tissue levels in DSM. 
Western blot analysis detected protein expression for KV7.2 and KV7.3 channel subunits in 
DSM tissue. In isolated DSM cells, immunocytochemical experiments further revealed 
protein expression for KV7.2 and KV7.3 channel subunits localized within the vicinity of 
the cell membrane.   
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Figure 3.8. ICA-069673 decreases global intracellular Ca2+ levels in freshly-isolated 
DSM cells. A) Original recordings illustrating that ICA-069673 (10 µM) significantly 
decreased global intracellular Ca2+ levels in a freshly-isolated DSM cell. B) Summarized 
data representing the reduction in global intracellular Ca2+ levels by 10 µM ICA-069673 
(n=11, N=5; *P<0.05). C) An original recording representing the lack of effect of ICA-
069673 (10 µM) in decreasing global intracellular Ca2+ levels in the presence of the L-type 
CaV channel blocker nifedipine (1 µM) in a DSM cell. D) Summarized data representing 
the effects of ICA-069673 (10 µM) on global intracellular Ca2+ in the presence of 
nifedipine (1 µM) (n=10, N=4; P>0.05) in DSM cells. Data are reported as the ratio of fura-
2 AM fluorescent emission at 510 nm with excitation at 340 and 380 nm; ns, non-
significant. 
 
Pharmacological studies demonstrated that ICA-069673 significantly hyperpolarized the 
membrane potential, inhibited DSM spontaneous action potentials, and decreased global 
intracellular Ca2+ concentrations of DSM cells. Functional studies on DSM contractility 
revealed that ICA-069673 inhibits spontaneous, pharmacologically-induced, and nerve-
evoked contractions in DSM isolated strips.  
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The inhibitory effects of ICA-069673 on DSM excitability and contractility were 
attenuated by the KV7.1-KV7.5 inhibitor XE991, supporting the involvement of KV7 
channel subtypes in the regulation of DSM excitability and contractility. Our combined 
results suggest a critical role for KV7.2- and KV7.3-containing channels in DSM excitation-
contraction coupling. 
From all KV7 channel subunits, mRNA transcripts for KV7.1 and KV7.2 channels 
are most predominant in guinea pig DSM cells [7]. The expression of KV7 channels at the 
protein-level has only been identified in DSM tissue via immunohistochemistry [7, 8], 
which has the inherent limitation of potentially detecting KV7 channel expression from 
neighboring non-DSM cell types such as neurons or interstitial cells in the absence of cell-
specific labelling. Thus, as illustrated in Figure 3.1, novel immunocytochemical 
experiments with confocal microscopy reveal the expression of KV7.2- and KV7.3-
containing channels in isolated DSM cells, where these channels localize within the 
vicinity of the cell membrane. Further, Western blot experiments detected protein 
expression for both KV7.2 and KV7.3 channel subunits in DSM (Figure 3.1), consistent 
with the previous reports by our group and others using immunohistochemistry [7, 8]. 
KV7 channel activators and inhibitors such as retigabine and XE991 have provided a useful 
pharmacological approach for elucidating KV7 channel roles in urinary bladder function 
[4, 7-9, 26-28, 34]. However, retigabine and XE991 do not effectively distinguish among 
KV7.2-KV7.5 and KV7.1-KV7.5 channel subtypes, respectively.  
The lack of subtype selectivity of these pharmacological modulators has thus been 
a substantial limitation for gaining an improved understanding of the KV7 channel subtypes 
most critical to DSM function. A novel KV7 channel activator, ICA-069673, has 
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demonstrated selectivity for heteromeric KV7.2/KV7.3 channels and is a pyrimidine 
analogue of N-(6-chloro-pyridin-3-yl)-3,4-difluoro-benzamide (ICA-27243) [30, 35, 36]. 
Though less potent than its related analog ICA-27243, ICA-069673 displays greater 
efficacy and improved selectivity for heteromeric KV7.2/KV7.3 over KV7.1 channels [30]. 
In contrast to retigabine, which binds to the pore region (S5-S6) of KV7.2-KV7.5 channels 
[37], evidence suggests that ICA-069673 is among an emerging novel class of compounds 
known as “gating modifiers”, named so for their ability to bind to the S1-S4 voltage-
sensing domain of KV7 channels [31, 36, 38]. The functional studies on DSM contractility 
revealed that ICA-069673 effectively inhibited spontaneous phasic contractions in DSM 
isolated strips in a concentration-dependent manner (Figure 3.2). Occurring locally in 
DSM, spontaneous phasic contractions do not initiate urine voiding; however, these 
contractile events have been associated with involuntary non-voiding contractions 
observed in some forms of OAB [11, 12]. The inhibition of DSM contractility was not 
observed when ICA-069673 was administered in the presence of the KV7 channel inhibitor 
XE991, which indicates the inhibitory effects of ICA-069673 on spontaneous phasic 
contractions were mediated by KV7 channels (Figure 3.2).  
Similarly, DSM phasic contractions induced by the muscarinic receptor agonist 
carbachol (0.1 µM) or through slight membrane depolarization by KCl (20 mM) were 
significantly inhibited by ICA-069673. Under conditions of high extracellular K+ (60 mM), 
which significantly changes the driving force for K+ and causes sustained membrane 
depolarization that in turn activates the L-type CaV channels, ICA-069673 (10 µM) had a 
rather modest inhibitory effect on DSM tone (~10% of the maximum relaxation, Figure 
3.5). In contrast, the subsequent inhibition of L-type CaV channels using nifedipine 
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decreased DSM tonic contractions by approximately seven -fold in comparison to ICA-
069673 alone (Figure 3.5).  
These results support the concept that ICA-069673 does not directly inhibit L-type 
CaV channels in DSM. These data are consistent with a previous report where ICA-069673 
(30 µM) demonstrated no direct effects on L-type CaV channels, as well as voltage-gated 
Na+ (Nav1.5), hERG, KV7.1, or GABAA channels at 10 µM [30]. We next examined how 
ICA-069673 affects nerve-evoked DSM contractions induced by EFS. The results showed 
that ICA-069673 significantly decreased 10 Hz EFS-induced contractions (Figure 3.6) and 
contractions induced over a large range of EFS frequencies (3.5-50 Hz) (Figure 3.7), 
indicating that KV7.2- and KV7.3-containing channels sensitive to ICA-069673 are 
essential regulators of urinary bladder nerve-evoked contractions. Qualitatively, the effects 
of ICA-069673 on DSM contractility were consistent with those reported for retigabine 
[7]. This similarity suggests the involvement of the same molecular targets by retigabine 
and ICA-069673, indicating a prominent role for the KV7.2- and KV7.3-containing 
channels in DSM function. 
The contraction of DSM is ultimately triggered in response to a rise in the 
intracellular Ca2+ concentration [1]. Therefore, we sought to determine the effects of ICA-
069673 on global intracellular Ca2+ levels and to elucidate the role of the KV7.2/KV7.3 
channels in controlling DSM cell Ca2+ signaling by conducting ratiometric fluorescence 
Ca2+ imaging on isolated DSM cells. ICA-069673 (10 µM) significantly decreased global 
intracellular Ca2+ levels in DSM cells (Figure 3.8), consistent with the inhibitory effects 
of ICA-069673 on DSM contractility. The reduction of intracellular Ca2+ concentrations 
by ICA-069673 is in agreement with the opposite phenomenon where the KV7 channel 
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inhibitor XE991 increased the frequency of Ca2+ oscillations in DSM tissue [8]. To further 
assess the interactions of the KV7.2/KV7.3 channels with the L-type CaV channels, we 
investigated the effects of ICA-069673 in the presence of the L-type CaV channel blocker 
nifedipine (1 µM). The results showed that when L-type CaV channels were inhibited by 
nifedipine, ICA-069673 had no effect on global intracellular Ca2+ levels (Figure 3.8). 
These observations support the concept that in isolated DSM cells, ICA-069673 reduces 
global intracellular Ca2+ levels by inhibiting L-type CaV channels indirectly through 
activation of KV7.2- and KV7.3-containing channels and associated membrane 
hyperpolarization.  
Our group was the first to record spontaneous action potentials in freshly-isolated 
DSM cells and to report the effects of retigabine on the action potentials using the 
perforated patch-clamp technique in current-clamp mode [7]. The current study revealed 
that ICA-069673 (10 µM) hyperpolarized the membrane potential and inhibited 
spontaneous action potentials in isolated DSM cells (Figure 3.9). The hyperpolarizing 
effects of ICA-069673 on the DSM cell membrane potential were comparable to that of 
retigabine [7]. ICA-069673-mediated hyperpolarization was blocked when the KV7 
channels were inhibited by XE991 (Figure 3.9). XE991 alone induced depolarization as 
measured with the perforated patch-clamp technique (Figure 3.9) consistent with a 
previous finding using the conventional whole cell patch-clamp technique [8]. The 
combined results from our patch-clamp studies indicate a key role for KV7.2- and KV7.3-
containing channels in regulating spontaneous action potentials and the resting membrane 
potential of isolated DSM cells. 
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In conclusion, the current study using the novel KV7.2/KV7.3 channel activator 
ICA-069673, provides strong evidence to suggest a critical role for the KV7.2- and KV7.3-
containing channels in DSM function at both cellular and tissue levels. Pharmacological 
activation of KV7.2/KV7.3 channels with ICA-069673 hyperpolarized the membrane 
potential and inhibited spontaneous action potentials in freshly-isolated DSM cells 
preventing Ca2+ influx through L-type CaV channels to reduce global intracellular Ca
2+ 
concentrations, and caused relaxation of DSM isolated strips.  
While our study demonstrates important roles for KV7.2- and KV7.3-containing 
channels in DSM cells and tissue, evidence suggests a prominent role for KV7.4 and KV7.5 
channels in non-DSM human smooth muscle tissues [22, 39, 40]. Therefore, it is important 
for future studies to investigate the expression and function of KV7 channels in human 
DSM at both the whole tissue and single-cell levels, which is critical for further evaluating 
their therapeutic potential as novel targets for the treatment of OAB.  
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Figure 3.9. ICA-069673 hyperpolarizes the resting membrane potential and inhibits 
spontaneous action potentials in freshly-isolated DSM cells. A) An original membrane 
potential recording in current-clamp mode of a DSM cell exhibiting spontaneous action 
potentials. ICA-069673 (10 µM) hyperpolarized the DSM cell membrane potential and 
further abolished the spontaneous action potentials in a manner reversible upon washout. 
B) An original membrane potential recording of a DSM cell that does not exhibit 
spontaneous action potentials. ICA-069673 (10 µM) hyperpolarized the membrane 
potential, an effect which was recovered upon washout. C) An original membrane potential 
recording illustrating that the KV7 channel inhibitor XE991 (10 µM) depolarized the DSM 
cell membrane potential. D) A continuation of the recording in (C) illustrating that in the 
presence of XE991 (10 µM), the hyperpolarizing effects of ICA-069673 (10 µM) on the 
DSM cell membrane potential are attenuated. E) Summarized data for the effects of ICA-
069673 (10 µM), washout of ICA-069673, XE991 (10 µM), and ICA-069673 (10 µM) in 
the presence of XE991 (10 µM) on the membrane potential. The Y-axis represents the 
change in the membrane potential, either depolarization (+) or hyperpolarization (-). With 
the exception of when ICA-069673 was applied in the presence of XE991, the control 
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period was in the absence of any pharmacological treatment. When determining the effects 
of ICA-069673 in the presence of XE991, the control was the 5-min period of stable 
recording before the addition of ICA-069673 (i.e. in the presence of XE991 only). * 
indicates statistical difference of P<0.05 versus the control for the treatments shown; # 
P<0.05 and ## P<0.01 indicate statistically significant differences for the comparisons 
shown. Each data-point in (E) is n=5-7, N=5-6. 
 
Table 3.1. IC50 and maximal efficacy values for the effects of ICA-069673 on 
spontaneous phasic, pharmacologically-induced, and 10 Hz EFS-induced 
contractions in guinea pig DSM isolated strips. IC50: Mean (95% confidence interval), 
Maximal efficacy: Mean±SEM. n/a, not applicable. *Maximum efficacy is normalized to 





7KV7 CHANNEL PHARMACOLOGICAL ACTIVATION WITH THE NOVEL 
ACTIVATOR ML213: ROLE FOR HETEROMERIC KV7.4/KV7.5 CHANNELS IN 
GUINEA PIG DETRUSOR SMOOTH MUSCLE FUNCTION 
 
ABSTRACT 
Voltage-gated KV7 channels (KV7.1-KV7.5) are important regulators of the cell membrane 
potential in detrusor smooth muscle (DSM) of the urinary bladder. This study sought to 
further the current knowledge of KV7 channel function at the molecular, cellular, and tissue 
levels in combination with pharmacological tools. We used isometric DSM tension 
recordings, ratiometric fluorescence Ca2+ imaging, amphotericin-B perforated patch-clamp 
electrophysiology, and in situ proximity ligation assay (PLA) in combination with the 
novel compound N-(2,4,6-Trimethylphenyl)-bicyclo[2.2.1]heptane-2-carboxamide 
(ML213), an activator of KV7.2, KV7.4 and KV7.5 channels, to examine their physiological 
roles in guinea pig DSM function. ML213 caused a concentration-dependent (0.1-30 µM) 
inhibition of spontaneous phasic contractions in DSM isolated strips; effects blocked by 
the KV7 channel inhibitor XE991 (10 µM). ML213 (0.1-30 µM) also reduced 
pharmacologically-induced and nerve-evoked contractions in DSM strips. Consistently, 
ML213 (10 µM) decreased global intracellular Ca2+ concentrations in fura-2 loaded DSM 
isolated strips. Perforated patch-clamp electrophysiology revealed ML213 (10 µM) caused 
an increase in the amplitude of whole cell KV7 currents. Further, in current-clamp mode of 
                                                           
7 Provence A, Angoli D, Petkov GV. KV7 Channel Pharmacological Activation with the Novel Activator ML213: Role for Heteromeric 
KV7.4/KV7.5 Channels in Guinea Pig Detrusor Smooth Muscle Function. J Pharmacol Exp Ther. 2017 Oct 30. pii: jpet.117.243162.  
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the perforated patch-clamp, ML213 hyperpolarized DSM cell membrane potential in a 
manner reversible by washout or XE991 (10 µM), consistent with ML213 activation of 
KV7 channel currents. Pre-application of XE991 (10 µM) not only depolarized the DSM 
cells, but also blocked ML213-induced hyperpolarization, confirming ML213 selectivity 
for KV7 channel subtypes. In situ PLA revealed co-localization and expression of 
heteromeric KV7.4/KV7.5 channels in DSM isolated cells. These combined results suggest 
that ML213-sensitive KV7.4-and KV7.5-containing channels are essential regulators of 
DSM excitability and contractility. 
INTRODUCTION  
Voltage-gated KV7 channels (KV7.1-KV7.5), encoded by KCNQ genes (KCNQ1-
KCNQ5), are critically involved in establishing and maintaining the cell membrane 
potential of many excitable cells and tissue types [17, 20-22, 24, 40, 41]. In addition, 
emerging new evidence points to potential physiological roles for the KV7 channels in 
detrusor smooth muscle (DSM), the main muscular component of the urinary bladder [7-
9, 26, 28, 34, 40, 42, 43].  
Recent studies from our laboratory and others show that KV7 channels serve key 
functional roles in regulating DSM function in rats [28, 34], guinea pigs [7, 8, 42], pigs 
[28], and humans [9, 44]. KV7 channel activation leads to hyperpolarization of the 
membrane potential thereby decreasing Ca2+-influx through L-type voltage-gated Ca2+ 
channels, which precludes Ca2+-dependent activation of myosin light chain kinase 
necessary for initiation of DSM contractility [4, 40]. KV7 channels were initially termed 
“M channels” as pioneering studies in frog sympathetic neurons demonstrated the 
suppression of KV7 channel currents in response to Gq/11-coupled muscarinic acetylcholine 
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receptor (mAChR) activation [45]. However, whether mAChRs are involved in the 
regulation of KV7 channel activity in DSM is not known. 
KV7 channel pore-forming α-subunits (KV7.1-KV7.5) have been shown to form 
both homo- and heteromeric channel conformations in experimental cell lines and native 
biological systems, which significantly expands the molecular and functional diversity of 
the KV7 channel family [15, 16]. Further, KV7 channel expression and function have also 
been shown to follow a certain level of subtype- and tissue-specificity. For example, KV7.1 
channels have established roles in the termination of the cardiac action potential [46], 
heteromeric KV7.2/KV7.3 channels underlie the neuronal “M-current” [47], and homo- or 
heteromeric combinations of KV7.4 and KV7.5 channel subtypes appear most critical in 
smooth muscle function [48]. Understandably, the development of novel KV7 channel 
pharmacological modulators with improved selectivity to distinguish among individual 
KV7 channel subtypes, is a highly sought endeavor. Indeed, several KV7 channel 
pharmacological modulators have emerged in recent years displaying improved selectivity 
for individual KV7 channel subtypes, including the KV7.2/KV7.3 channel activator ICA-
069673, a potent inhibitor of DSM excitability and contractility [42]. 
The compound N-(2,4,6-Trimethylphenyl)-bicyclo[2.2.1]heptane-2-carboxamide 
(ML213) is a novel KV7 channel activator initially characterized as being selective for 
KV7.2 and KV7.4 channel subtypes displaying ~80-fold selectivity over other KV7 channels 
[49, 50], as well as greater potency than other Kv7 activators such as retigabine and 
BMS204352 [23]. Subsequent in vitro pharmacological and electrophysiological studies in 
A7r5 vascular smooth muscle cells have reported ML213 as a potent activator of 
homomeric KV7.4 and KV7.5 channels and heteromeric KV7.4/KV7.5 channels [31]. 
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ML213 is currently the only known KV7 channel activator with this unique 
pharmacological selectivity profile. Nonetheless, studies seeking to identify whether 
heteromeric KV7 channels, specifically heteromeric KV7.4/KV7.5 channels, are expressed 
in DSM are currently absent. To identify the potential ML213-sensitive KV7 channel 
conformations expressed at the cellular level in DSM would greatly enhance our 
understanding of ML213 pharmacological effects on DSM function, while expanding our 
knowledge of the physiological roles of KV7 channel subtypes in the urinary bladder. 
Here, we used the novel KV7 channel activator ML213 to reveal insights into the 
subtype-specific KV7 channel functional roles in DSM excitability and contractility. This 
was achieved by a multidisciplinary experimental approach using isometric DSM tension 
recordings, ratiometric fluorescence Ca2+ imaging, and amphotericin-B perforated patch-
clamp electrophysiology. Further, in situ proximity ligation assay (PLA) was conducted to 
elucidate whether KV7.4 and KV7.5 channels, key pharmacological targets of ML213, co-
localize to form heteromeric channel complexes in DSM cells.  
MATERIALS AND METHODS 
Ethical approval for animal use. Protocols for the use of experimental animals in the 
current study are consistent with the NIH guidelines for the care and use of experimental 
animals and were reviewed and approved by the Institutional Animal Care and Use 
Committee (IACUC) of the University of South Carolina, protocols #2186-100859-072114 
and #2321-101157-092116.  
Animal housing, euthanization, and DSM tissue acquisition. 41 adult male Hartley-
Albino guinea pigs (Charles River Laboratories, Raleigh, NC, USA), aged 3-12 months 
and weighing 341-1,191 g (average 902±10 g), were utilized for this study. Animals were 
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housed in the Animal Resource Facilities at the University of South Carolina where they 
had free access to food and water and were exposed to 12 h light/dark cycles at room 
temperature (22-23 ºC). Animals were euthanized via CO2 inhalation using a 
SMARTBOX™ Automated CO2 Delivery System (Euthanex Corp, Palmer, PA, USA), 
followed by thoracotomy. The urinary bladder was then removed by an incision superior 
to the bladder neck. Following dissection, the urinary bladder is cut open via a longitudinal 
incision originating from the urethral orifice. This allows the bladder to be opened and 
pinned down flat to the base of a Sylgard-coated Petri dish. Under a dissection microscope, 
microscissors in combination with forceps are used to remove not only the urothelium, but 
the entire mucosal layer and lamina propria from the detrusor. 
DSM cell isolation and collection. DSM single cells were freshly isolated using a 
combination of papain and collagenase as previously described [51]. DSM cells were used 
for electrophysiological experiments or in situ PLA within 12 h after isolation. Intact DSM 
strips with urothelium removed were used for single cell isolation, isometric DSM tension 
recordings, and ratiometric fluorescence Ca2+ imaging.  
Isometric DSM tension recordings. Isometric DSM tension recordings were conducted 
as previously described on isolated DSM strips void of urothelium [51]. For experiments 
on spontaneous phasic, carbachol (CCh)-induced, and KCl-induced contractions, the DSM 
isolated strips were pretreated with the neuronal voltage-gated Na+ channel blocker 
tetrodotoxin (TTX, 1 µM) before the concentration-response effects of ML213 (0.1-30 
µM) were assessed. Electrical field stimulation (EFS)-induced DSM contractions were 
stimulated with a PHM-152I programmable stimulator (Med Associates, Inc., Georgia, 
VT, USA) in the absence of TTX. Ten or twenty Hz EFS frequency, respectively, was 
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delivered at 1 min intervals and ML213 (0.1-30 µM) was administered once a stable 
baseline and contraction amplitude was achieved. In a separate protocol, EFS-induced 
DSM contractions were stimulated at 3 min intervals over a wide range of frequencies (0.5, 
2.0, 3.5, 5, 7.5, 10, 12.5, 15, 20, 30, 40, 50 Hz) in the absence (control) and then in the 
presence of ML213 (1 or 3 µM). The inhibitory effects of ML213 were normalized to the 
control (taken to be 100%) and expressed as percentages, with 100% indicated no effect 
and 0% indicated complete DSM relaxation.  
Ratiometric fluorescence Ca2+ imaging. Global intracellular Ca2+ concentrations of 
isolated DSM strips were measured using the ratiometric fluorescence Ca2+ probe fura-2 
AM as previously described [32, 42]. 
Perforated patch-clamp electrophysiology. KV7 currents were recorded using the 
amphotericin-B perforated patch-clamp technique in voltage-clamp mode. At a holding 
potential of -10 mV (corrected for junction potential), KV7 currents were recorded by 
applying 500 ms voltage steps at 10 mV intervals from voltages ranging -80 mV to +40 
mV. To effectively isolate KV7 currents, recordings were made in the presence of the 
selective large conductance voltage- and Ca2+-activated K+ (BK) channel inhibitor 
paxilline (1 µM) and GdCl3 (50 µM), an inhibitor of non-selective cation channels and L-
type voltage-gated Ca2+ channels [17, 52]. The amphotericin-B perforated patch-clamp 
technique in current-clamp mode (I=0) was used to record the DSM cell membrane 
potential as previously described [7, 42]. 
In situ Proximity Ligation Assay (PLA). In situ PLA was performed on freshly-isolated 
DSM cells using the Duolink® in Situ orange starter kit goat/rabbit (Cat. No: DUO92106, 
Sigma-Aldrich, St. Louis, MO) according to the manufacturer’s instructions. DSM cells 
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underwent fixation in 2% paraformaldehyde (10 min, 37°C) followed by two 15-min 
washes in phosphate buffered saline. DSM cells were then blocked in Duolink blocking 
solution (30 min, 37°C). Subsequently, DSM cells were incubated with the anti-rabbit 
KV7.4 (Santa Cruz Biotechnology, Dallas, TX; Cat. No.: sc-50417) and anti-goat KV7.5 
(Cat. No.: sc-18048) antibodies or with the control anti-goat inositol triphosphate receptor 
(IP3R) antibody (Cat. No.: sc-28614), respectively, in Duolink antibody diluent solution 
overnight at 4°C, followed by 2x5 min washes in Duolink 1x wash buffer A solution. DSM 
cells were then incubated with the Duolink PLA probe anti-rabbit MINUS and anti-goat 
PLUS oligonucleotide-conjugated secondary antibodies (1 h, 37°C), followed by 2x5 min 
washes in Duolink 1x wash buffer A solution. DSM cells were then incubated in ligase-
ligation solution (30 min, 37°C), which hybridizes the two PLA MINUS and PLUS probes 
when in close proximity (<40 nm). Following ligation, DSM cells were washed 2x2 min 
in Duolink 1x wash buffer A solution. Finally, DSM cells were incubated in amplification-
polymerase solution (100 min, 37°C) containing nucleotides and fluorescently-labelled 
oligonucleotides. The oligonucleotide arm of one PLA probe is a primer for rolling-circle 
amplification (RCA). The fluorescently-labeled oligonucleotides hybridize to the RCA 
product thus permitting detection. Following amplification, DSM cells were washed 2x10 
min in 1x wash buffer B and then a 1 min wash in 0.01x wash buffer B. Slides were then 
mounted using minimal volume of Duolink in situ mounting medium with 4',6-diamidino-
2-phenylindole, dihydrochloride (DAPI). PLA signals (Duolink In Situ Detection Reagents 
Orange (λexcitation/emission=554/576 nm)) were detected using laser scanning LSM 700 
confocal microscope (Carl Zeiss, Germany) with a 63x oil immersion objective. 
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Solutions and drugs. Nominally Ca2+-free dissection solution contained the following (in 
mM): 80 monosodium glutamate; 55 NaCl; 6 KCl; 10 glucose; 10 4-(2-hydroxyethyl) 
piperazine-1-ethanesulfonic acid (HEPES); 2 MgCl2; NaOH was used to attain pH 7.3. 
Ca2+-containing physiological saline solution contained the following (in mM): 119 NaCl; 
4.7 KCl; 24 NaHCO3; 1.2 KH2PO4; 2.5 CaCl2; 1.2 MgSO4; 11 glucose; that was aerated 
with 95% O2/5% CO2 to attain pH 7.4. Physiological bath solution utilized for patch-clamp 
experiments was composed of the following (in mM): 134 NaCl; 6 KCl; 1 MgCl2; 2 CaCl2; 
10 glucose; 10 HEPES; and NaOH was used to obtain pH 7.4. The patch-pipette solution 
contained (in mM): 110 potassium aspartate; 30 KCl; 10 NaCl; 1 MgCl2; 10 HEPES; 0.05 
ethylene glycol-bis(2-aminoethylether)-N,N,N',N'-tetraacetic acid (EGTA); NaOH was 
used to adjust the pH to 7.2. Amphotericin-B stock solution was prepared daily in dimethyl 
sulfoxide (DMSO) and was included in the pipette solution (200-300 μg/ml) before the 
experiment and was replaced every 1-2 h. ML213, TTX citrate, and XE991 were purchased 
from Tocris Bioscience (Minneapolis, MN). Fura-2 AM was purchased from Life 
Technologies (Cat No.: F1221, Carlsbad, CA). ML213 and Fura-2 AM were dissolved in 
DMSO, while XE991 and TTX citrate were dissolved in double-distilled water. All other 
chemicals were obtained from Fisher Scientific (Waltham, MA), Sigma-Aldrich, or 
Worthington Biochemical Corp. (Lakewood, NJ).  
Data Analysis and Statistics. Isometric DSM tension recording experiments for 
spontaneous phasic, pharmacologically-induced, and nerve-evoked contractions were 
conducted and analyzed as previously described [7, 42, 51]. Perforated whole cell patch-
clamp experiments were performed and analyzed using pCLAMP 10.3. Where specified in 
the summarized data, “n” represents the number of freshly-isolated DSM strips or cells, 
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and “N” represents the number of guinea pigs. Statistical analyses were based on the 
number of DSM cells or strips, respectively (i.e. “n”). For spontaneous contraction 
experiments, statistical analysis for the comparison of ML213 in the absence or presence 
of XE991, two-way ANOVA test was performed followed by Bonferroni post-hoc test. 
Paired Student’s t-tests were used for the remaining statistical analyses. Summarized data 
are reported as means±SEM. P values <0.05 were considered statistically significant. Corel 
Draw Graphic Suite X3 software (Corel Co., Mountain View, CA) and GraphPad Prism 
4.03 software (La Jolla, CA) was used for data illustration. 
RESULTS 
ML213 decreased spontaneous phasic contractions in DSM isolated strips. To explore 
the physiological effects of KV7 channel pharmacological activation with ML213 on 
spontaneous phasic contractions, we conducted isometric DSM tension recordings on DSM 
isolated strips. ML213 (0.1-30 µM) caused a concentration-dependent inhibition of 
spontaneous phasic contractions in DSM isolated strips (n=6, N=6; P<0.05; Fig. 4.1). 
Pretreatment of DSM isolated strips with the KV7 channel inhibitor XE991 (10 µM) 
abolished ML213 (0.1-30 µM)-induced inhibition of spontaneous phasic contractions, 
confirming selectivity for KV7 channels (n=6 N=6; P<0.05; Fig. 4.1). IC50 and maximal 
efficacy values for ML213 on spontaneous phasic contractions are reported in Table 4.1. 
ML213 decreased KCl-induced contractions in DSM isolated strips. Next, we 
elucidated the effects of ML213 (0.1-30 µM) on DSM contractions induced by mild 
membrane depolarization using 20 mM KCl. In the presence of 20 mM KCl, ML213 (0.1-
30 µM) caused a concentration-dependent inhibition of DSM contractions and exhibited a 
decrease in potency in comparison to ML213 inhibitory effects on spontaneous phasic 
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contractions (see Table 4.1) (n=7, N=7; P<0.05; Fig. 4.2). To further explore the role of 
K+ conductance in ML213-induced inhibition of DSM contractions and the potential direct 
interaction with L-type voltage-gated Ca2+ channels, we tested the effects of ML213 (10 
μM) on tonic DSM contractions stimulated by high 60 mM KCl. Here, ML213 (10 μM) 
decreased 60 mM KCl-induced muscle tone to only 74±3.5% of the control (n=8, N=4; 
P<0.01; Fig. 4.4). Subsequent application of the L-type voltage-gated Ca2+ channel 
inhibitor nifedipine, however, caused an inhibitory effect significantly greater in 
comparison to ML213, decreasing DSM tone to 39.7±6.4% of the control (n=8, N=4; 
P<0.001; Fig. 4.4). The difference between the inhibitory effects of ML213 (10 µM) and 
nifedipine on tonic DSM contraction were statistically significant (n=8, N=4; P<0.001; 
Fig. 4.4). These data suggest ML213 does not directly inhibit L-type voltage-gated Ca2+ 
channel activity in DSM. 
Carbachol attenuated ML213-induced inhibition of DSM contractions in a 
concentration-dependent manner. We next sought to determine the potential 
involvement of muscarinic acetylcholine receptor (mAChR) signaling in ML213-induced 
inhibition of DSM contractility. This was achieved by examining the inhibitory effects of 
ML213 (0.1-30 µM) on DSM contractions stimulated by the mAChR agonist CCh (0.1 or 
1 µM). ML213 (0.1-30 µM) caused a concentration-dependent inhibition of both 0.1 µM 
and 1 µM CCh (n=6, N=6 for both; P<0.05; Fig. 4.3). However, in comparison to 0.1 µM, 
mAChR stimulation with 1 µM CCh markedly reduced the potency of ML213 on DSM 
contraction amplitude and muscle force (see Table 4.1). .IC50 and maximal efficacy values 




Figure 4.1. KV7 channel pharmacological activation with ML213 leads to an 
inhibition of spontaneous phasic contractions in DSM isolated strips. A) A 
representative isometric DSM tension recording demonstrating that ML213 (0.1-30 µM) 
inhibited spontaneous phasic contractions in a DSM isolated strip. B) A representative 
isometric DSM tension recording illustrating the KV7 channel inhibitor XE991 (10 µM) 
abolished the inhibitory effects of ML213 (0.1-30 µM) on DSM spontaneous phasic 
contractions. C-F) Cumulative concentration-response curves for ML213 on DSM phasic 
contraction: C) amplitude, D) muscle force, E) duration and F) frequency in the absence 
and presence of the KV7 channel inhibitor XE991 (n=6, N=6; *P<0.05, **P<0.01, and 
***P<0.001). #P<0.05, ##P<0.01, and ###P<0.001 indicate statistical significance in the 
effects of ML213 on spontaneous phasic contractions in the absence (control) versus 




Figure 4.2. KV7 channel pharmacological activation with ML213 leads to an 
inhibition of 20 mM KCl-induced phasic contractions in DSM isolated strips. A) A 
representative isometric DSM tension recording demonstrating the concentration-
dependent inhibition of 20 mM KCl-induced DSM phasic contractions by ML213 (0.1-30 
µM). B-E) Cumulative concentration-response curves for the inhibitory effects of ML213 
on DSM phasic contraction: B) amplitude, C) muscle force, D) duration and E) frequency 
(n=7, N=7; *P<0.05 and ***P<0.001). See Table 4.1 for potency and maximum efficacy 
values. 
 
ML213 decreased nerve-evoked contractions in DSM isolated strips. To further 
explore potential roles for mAChRs in ML213-induced inhibition of DSM contractions, 
ML213 (0.1-30 µM) inhibitory effects were examined on nerve-evoked contractions 
stimulated by either 10 Hz or 20 Hz EFS. ML213 (0.1-30 µM) caused a concentration-
dependent inhibition of EFS-induced contractions stimulated continuously at both 10 and 




Figure 4.3. Differential inhibitory effects of ML213 and nifedipine on 60 mM KCl-
induced tonic contractions in DSM isolated strips. A) A representative isometric DSM 
tension recording demonstrating the differential effects of 10 µM ML213 and 1 µM 
nifedipine upon a depolarization-induced DSM tonic contraction caused by 60 mM KCl in 
a DSM isolated strips. B) Summarized data demonstrating the differential inhibitory effects 
of ML213 (10 µM) and nifedipine (1 µM) on DSM 60 mM KCl-induced tonic contraction 
(n=8, N=4; ##P<0.01 vs. control, and **P<0.001 ML213 vs. nifedipine, respectively). 
 
IC50 and maximal efficacy values for ML213 on 10 Hz and 20 Hz EFS-induced contractions 
are reported in Table 4.1. In comparison to 10 Hz EFS, the potency of ML213 on 20 Hz 
EFS-induced contractions was reduced by more than two-fold (see Table 4.1). Next, 
ML213 (1 or 3 µM) inhibitory effects were examined on contractions induced over a range 
of EFS frequencies (0.5-50 Hz). ML213 (1 or 3 µM) decreased the amplitude of 10-50 Hz 
EFS-induced contractions (n=6, N=6; P<0.05; Fig. 4.6).  
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ML213 decreased global intracellular Ca2+ concentrations in DSM isolated strips.  We 
next aimed to assess the effects of ML213 on global intracellular Ca2+ concentrations of 
isolated DSM strips loaded with fura-2. This was achieved using the ratiometric 
fluorescence Ca2+ indicator fura-2 AM and measuring the emission at 510 nm with 
excitation at 340 and 380 nm. Under control conditions in the absence of ML213, the mean 
intensity (F340/F380) was 0.84±0.05 (n=7, N=6) and in the presence of ML213 (10 µM) the 
mean F340/F380 ratio was decreased to 0.77±0.05 (n=7, N=6; P<0.05; Fig. 4.7). These results 
suggest KV7 channel pharmacological activation with ML213 critically regulates global 
intracellular Ca2+ concentrations in DSM isolated strips and thus DSM contractility. 
ML213 decreased global intracellular Ca2+ concentrations in DSM isolated strips.  We 
next aimed to assess the effects of ML213 on global intracellular Ca2+ concentrations of 
isolated DSM strips loaded with fura-2. This was achieved using the ratiometric 
fluorescence Ca2+ indicator fura-2 AM and measuring the emission at 510 nm with 
excitation at 340 and 380 nm. Under control conditions in the absence of ML213, the mean 
intensity (F340/F380) was 0.84±0.05 (n=7, N=6) and in the presence of ML213 (10 µM) the 
mean F340/F380 ratio was decreased to 0.77±0.05 (n=7, N=6; P<0.05; Fig. 4.7). These results 
suggest KV7 channel pharmacological activation with ML213 critically regulates global 
intracellular Ca2+ concentrations in DSM isolated strips and thus DSM contractility. 
ML213 enhanced the amplitude of whole cell KV7 currents in freshly-isolated DSM 
cells. We next sought to examine the pharmacological effects of ML213 on whole cell KV7 
currents using the perforated patch-clamp technique in voltage-clamp mode. In the first 
series of experiments, KV7 currents were recorded at a holding potential of -10 mV wherein 
500 ms voltage steps were applied at 10 mV intervals from -80 mV to +40 mV.   
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Figure 4.4. KV7 channel pharmacological activation with ML213 leads to an 
inhibition of CCh-induced DSM phasic contractions. A) A representative isometric 
DSM tension recording demonstrating the concentration-dependent inhibition of 0.1 µM 
CCh-induced phasic contractions in a DSM isolated strip. B) A representative isometric 
DSM tension recording demonstrating the concentration-dependent inhibition of 1 µM 
CCh-induced phasic contractions in a DSM isolated strip. C-F) Cumulative concentration-
response curves for ML213 on CCh (0.1 or 1 µM)-induced DSM phasic contraction C) 
amplitude and D) muscle force, E) duration, and F) frequency (n=6, N=6 for both data sets; 
#P<0.05, ###P<0.001). See Table 4.1 for potency and maximum efficacy values.  
 
To effectively isolate KV7 currents, recordings were made in the presence of the selective 
large-conductance voltage- and Ca2+- activated K+ (BK) channel inhibitor paxilline (1 µM) 





Figure 4.5. KV7 channel pharmacological activation with ML213 leads to an 
inhibition of nerve-evoked contractions induced by 10 Hz and 20 Hz EFS in DSM 
isolated strips. A) A representative isometric DSM tension recording demonstrating the 
concentration-dependent inhibition of 10 Hz EFS-induced contractions by ML213 (0.1-30 
µM) in DSM isolated strips. B)  A representative isometric DSM tension recording 
illustrating the concentration-dependent inhibition of 20 Hz EFS-induced contractions by 
ML213 (0.1-30 µM) in DSM isolated strips. C-D) Cumulative concentration-response 
curves for ML213 on DSM EFS-induced: C) contraction amplitude and D) muscle force 
(n=7, N=6 for 10 Hz; n=6, N=6 for 20 Hz; *P<0.05 for 10 vs. 20 Hz). See Table 4.1 for 
potency and maximum efficacy values.  
 
Further, the more depolarized holding potential of -10 mV that we used ensures 
inactivation of other non-KV7 K
+ channels, such as inward-rectifying K+ channels [53]. 
ML213 (10 µM) caused a significant increase in the amplitude of whole cell KV7 currents 
at all voltages from -50 to +40 mV (n=7, N=5; P<0.05; Fig. 4.8). We further sought to 
examine the time course for the pharmacological effects of ML213 on KV7 currents in 
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DSM cells. This was achieved using a one-step voltage-clamp protocol with a 5 s duration 
stimulus applied every 20 s from a -10 mV holding potential to +40 mV. ML213 (10 µM) 
 
Figure 4.6. ML213 decreases 0.5-50 Hz EFS-induced contractions in DSM isolated 
strips. A-C) The original isometric DSM tension recordings of 0.5-50 Hz EFS-induced 
contractions in DSM isolated strips A) before (control), and after the addition of B) 1 µM 
ML213, and C) 3 µM ML213. D-E) Cumulative frequency-response curves demonstrating 
the inhibitory effects of D) 1 µM ML213 and E) 3 µM ML213 on the amplitude of 0.5-50 
Hz EFS-induced contractions in DSM isolated strips (n=6, N=6 for both data sets; *P<0.05, 
**P<0.01, and ***P<0.001).  
 
caused a significant increase in the whole cell KV7 current amplitude by 106.7±54.95% 
and 48.4±21.33%, respectively, in comparison to the control (n=8, N=5, P<0.05; Fig. 4.9).  
ML213 hyperpolarizes the resting membrane potential in freshly-isolated DSM cells. 
Using the perforated whole cell patch-clamp technique in current-clamp mode, we next 
sought to determine the physiological role of ML213-sensitive KV7 channels in regulating 
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the DSM cell membrane potential. ML213-induced inhibitory effects were examined in 6 
DSM isolated cells from 6 different animals, which had an average resting membrane 
potential of -22±4.2 mV. ML213 hyperpolarized the DSM cell membrane potential from 
the control value of -22±4.2 mV to -42.6±4.2 mV (n=6, N=6; P<0.05; Fig. 4.10). ML213-
induced DSM cell membrane hyperpolarization was fully reversible by washout of ML213 
(Fig. 4.10). On the contrary, XE991 (10 µM) depolarized the DSM cell membrane potential 
from -29.8±4.3 to -18.7±2.7 and blocked ML213 (10 µM) hyperpolarization at -20.6±2.8 
(n=8, N=4; P<0.05; Fig. 4.10), confirming ML213 selectivity for the KV7 channels. XE991 
(10 µM) was also effective in reversing the hyperpolarizing effects of ML213 from -
39.2±9.2 to -23.2±5.5 (control was -26.6±7.2) (n=7, N=6; P<0.05; Fig. 4.11). These 
combined results suggest key involvement for ML213-sensitive KV7.2, KV7.4, and KV7.5 
channels in regulating the DSM cell membrane potential.  
KV7.4 and KV7.5 channel α-subunits assemble to form heteromeric KV7.4/KV7.5 
channel subtypes in freshly-isolated DSM cells. Using in situ PLA, we sought to 
determine whether KV7.4 and KV7.5 channels, among the key targets of ML213, form 
heteromeric channels in freshly-isolated DSM cells. In situ PLA demonstrated KV7.4 and 
KV7.5 channel subunits associate to form heteromeric KV7.4/KV7.5 channels in isolated 
DSM cells. As shown in Figure 4.12, in situ PLA experiments demonstrated the co-
localization of KV7.4 and KV7.5, channel α-subunits within 40 nm and within the vicinity 
of the DSM cell membrane. Primary antibodies against the IP3R, which would not be 
expected to co-localize with members of the KV7 channel family, were used as a negative 
control. Co-incubation of the KV7.4 channel primary antibody with the primary antibody 
of the IP3Rs yielded no PLA fluorescent signal (Fig. 4.12). These combined results suggest 
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that KV7.4 and KV7.5 channel subunits assemble to form heteromeric KV7.4/KV7.5 channel 
subtypes in DSM cells.  
DISCUSSION 
The current study utilized the novel compound ML213, a potent and selective activator of 
KV7.2, KV7.4, and KV7.5-containing channels, to elucidate their physiological roles in 
DSM excitability and contractility. ML213 inhibited spontaneous, pharmacologically-
induced, and nerve-evoked DSM contractions and decreased global intracellular Ca2+ 
concentrations in DSM strips. ML213 enhanced whole cell KV7 currents and 
hyperpolarized the resting membrane potential of freshly-isolated DSM cells. In situ PLA 
studies further revealed the expression of heteromeric KV7.4/KV7.5 channels within the 
vicinity of the DSM cell membrane, which are key pharmacological targets of ML213. 
Previous studies on guinea pig, including those from our group, have demonstrated a role 
for KV7 channels in DSM function through the use of KV7 channel pharmacological 
modulators [7, 8, 42]. ML213 promoted concentration-dependent inhibition of spontaneous 
phasic contractions with IC50 values of 1.1 and 0.7 µM, respectively (Fig. 4.1 and Table 
4.1). Consistently, the inhibitory effects of ML213 on DSM contractile activity in our study 
are consistent with previous reports in human and pig DSM [9, 28, 44]. Based on our data,  
ML213 displays greater potency in comparison to retigabine, the KV7.1 channel activator 
L-364373, and the KV7.2/KV7.3 channel activator ICA-069673 for inhibiting DSM 
spontaneous phasic contraction amplitude and muscle force [7, 8, 42]. ICA-069673 and 
ML213 have each been demonstrated to potently activate homomeric KV7.4 channels, 
however, the key distinction between these two compounds was the ability for ML213 to 




Figure 4.7. ML213 decreases global intracellular Ca2+ concentrations in DSM isolated 
strips. A) Original recordings illustrating that ML213 (10 µM) significantly decreased 
global intracellular Ca2+ levels in a fura 2-loaded DSM strip. B) Summarized data 
representing the reduction in global Ca2+ levels by 10 µM ML213 in DSM isolated strips 
(n=7, N=6; *P<0.05).  
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Figure 4.8. ML213 (10 µM) enhanced whole cell KV7 currents in freshly-isolated DSM 
cells. A) Representative whole cell patch-clamp recordings illustrating the potentiation of 
KV7 currents induced by the introduction of ML213 in the bath external solution. Paxilline 
(1 µM) and GdCl3 (50 µM) were present in the solution. B) Current-voltage relationships 
obtained in the absence (control) or presence of 10 µM ML213 in a whole cell voltage-
clamp recording. The two curves represent the current–voltage relationship expressed as 
normalized current in the absence or presence of 10 µM ML213 (n=7, N=5, *P<0.05). Top 
left insert: 500 ms voltage-step protocol from -80 to +40 mV with holding potential at -10 
mV.   
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Figure 4.9. Time course of ML213-induced activation of KV7 channel currents in 
freshly-isolated DSM cells. A) Effects of ML213 on KV7 currents recorded using a one-
step voltage-clamp protocol with a 5 s duration stimulus applied every 20 s from a -10 mV 
holding potential to +40 mV. B) Representative traces (and voltage step used) of the 
experiment plotted in A) for the control, ML213 (10 µM) and washout of ML213. C) 
Summary data for the percentage of KV7 currents in the presence of ML213 compared to 
control at -10 and +40 mV respectively (n=8, N=5, *P<0.05). Summarized data illustrate 
the average of 4 to 6 points of each steady-state current. 
 
The greater capacity and potency for ML213 to inhibit spontaneous phasic, 
pharmacologically-induced, and EFS-induced DSM contractions (Figs. 4.1-4.6) in 
comparison to ICA-069673 [42], potentially implicates key involvement of KV7.4 or 
KV7.5-containing channels in DSM function. Similar observations were reported by studies 
using ML213 in rodent mesenteric arteries, where the KV7.4 channels subtypes are 
predominately expressed [23]  
62 
 
Figure 4.10. ML213 hyperpolarizes the resting membrane potential in freshly-
isolated DSM cells. A) A representative membrane potential recording in current-clamp 
mode illustrating that ML213 (10 µM) hyperpolarized the DSM cell membrane potential 
in a freshly-isolated DSM cell and that this effect was reversible by washout. B) 
Summarized data for the hyperpolarizing effects of ML213 (10 µM) on the DSM cell 
membrane potential (n=6, N=6; *P<0.05). C) A representative membrane potential 
recording in current-clamp mode demonstrating that XE991 (10 µM) depolarized the DSM 
cell membrane potential and blocked ML213 (10 µM) hyperpolarization in a freshly-
isolated DSM cell (D) Summarized data for XE991 (10 µM)-induced depolarization in 
freshly-isolated DSM cells and the lack of ML213 (10 µM) hyperpolarizing effects in the 
presence of 10 µM XE991 (n=8, N=4; *P<0.05).  
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Figure 4.11. ML213-induced hyperpolarization is reversed by KV7 channel inhibition 
with XE991. A) A representative current-clamp recording from a freshly-isolated DSM 
cell illustrating hyperpolarization of the DSM cell membrane potential by ML213 (10 µM) 
and that the ML213-induced hyperpolarization is reversed by the KV7 channel inhibitor 
XE991 (10 µM). B) Summary data for the hyperpolarizing effects of ML213 (10 µM) on 
the DSM cell membrane potential (n=7, N=5, *P<0.05, effects reversible by 10 µM XE991 
(n=7, N=5, #P<0.05). NS-non-significant.  
The ability of ML213 to inhibit DSM contractions was decreased in a 
concentration-dependent manner by the mAChR agonist CCh (Fig. 4.4). Consistently, 
ML213 exhibited a reduced potency on 20 Hz EFS-induced DSM contractions in 
comparison to 10 Hz (Fig. 4.5). ML213 inhibitory effects on CCh and EFS-induced DSM 
contractions are consistent with previous reports in pigs and humans [9, 28]. These results 
suggest that cellular pathways leading to the activation KV7 channels may potentially 
function in opposition to mAChR signaling. However, confirming the existence of 
functional link between KV7 channels and mAChRs in DSM will require additional future 
studies involving extensive pharmacological and electrophysiological approaches.  
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Parasympathetic nerves release ACh and ATP which act on mAChRs and purinergic 
receptors, respectively, to trigger bladder contraction during micturition [1, 2, 54]. ACh-
induced activation of mAChRs constitutes the primary mechanism initiating bladder 
contractions during micturition [1]. EFS evokes ACh release from parasympathetic nerve 
terminals, which leads to depolarization of the DSM cell membrane potential and 
associated DSM contractions [3]. While mAChR regulation of KV7 channel activity is 
consistent with early studies in neurons [45], whether a similar regulatory mechanism 
exists in DSM remains unknown. A recent study in airway smooth muscle reported that, 
unlike neuronal KV7 channels [55], mAChR activation by CCh did not exhibit significant 
inhibitory effects on KV7 currents [41]. Thus, KV7 channel activation in DSM may act in 
opposition to mAChRs through an indirect mechanism, for example, activation of L-type 
voltage-gated Ca2+ channels. Nonetheless, regulation of KV7 channels by mAChRs in DSM 
represents an interesting topic for future investigations. Consistent with ML213 inhibitory 
effects on DSM contractions, we further observed attenuation of global intracellular Ca2+ 
concentrations by ML213 in DSM strips (Fig. 4.7). 
For the first time, we report the activation of whole cell KV7 currents by ML213 in 
freshly-isolated DSM cells (Figs. 4.8-9). The use of a more depolarized holding potential 
(-10 mV) in our study ensures inactivation of other non-KV7 K
+ channels, such as inward-
rectifying K+ channels [53]. Also, at -10 mV holding potential, some of the KV7 channels 
are open and generate quantifiable currents, which are not contaminated by the presence of 
non-selective cation currents due to the inclusion of GdCl3. Thus, the stimulatory effects 
of ML213 on KV7 currents are evident (Fig. 4.8). Our data support the concept that the 
hyperpolarizing currents following addition of ML213 are a direct result of KV7 channel 
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pharmacological activation. In a series of experiments, we used short voltage steps (500 
ms) marginally revealing the kinetics of voltage-dependence of activation of the KV7 
channels. Alternatively, using longer voltage-step protocols (5 s) with multiple voltage 
steps may result in time-dependent rundown after several minutes of recording. Hence, we 
sought to examine the time course effects of ML213 on KV7 current activity by performing 
a one-step 5 s voltage-clamp protocol from a -10 mV holding potential to +40 mV at 20 s 
intervals (Fig. 4.9). This protocol allowed for the recording of KV7 channel currents 
without encountering substantial current run-down. The stimulatory effects of ML213 on 
KV7 currents were modest, but statistically significant (Fig. 4.8). Albeit, it is well-
established that small changes in DSM cell excitability can have pronounced effects on 
DSM contractility [56, 57]. Indeed, we observed very robust ML213 inhibitory effects on 
DSM contractility (Figs. 4.1-4.3).  
Overall, the experimental design for our electrophysiological experiments aimed 
not only to examine KV7 current activity and its response to pharmacological activation 
with ML213, but also to mimic a physiological environment characterized by a more 
depolarized resting membrane potential, which normally occurs under physiological 
conditions during the action potential. Activation of ML213-sensitive KV7 channels was 
further shown to hyperpolarize the DSM cell membrane potential (Fig. 4.10), consistent 
with ML213 inhibitory effects on global intracellular Ca2+ concentrations and DSM 
contractility. KV7 channel α-subunits are known to form functional homo- and heteromeric 
channel conformations in vitro and in vivo [14, 40], with KV7.4, and KV7.5 being prominent 
in smooth muscle tissues [58].  
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In vascular myocytes, ML213 has been shown to activate heteromeric KV7.4/KV7.5 
channels in addition to the homomeric channels composed either KV7.4 or KV7.5 channel 
α-subunits, respectively [31, 49]. In addition to KV7.2 channel expression in guinea pig 
DSM [7, 8, 42], KV7.4 [8], and KV7.5 [7, 8] channel α-subunits have been identified. 
However, whether these KV7 channel subunits, in particular KV7.4 or KV7.5, associate to 
form functional heteromers in DSM remains unknown. We confirmed the expression of 
heteromeric KV7.4/KV7.5 channels in isolated DSM cells using in situ PLA. PLA 
fluorescent signals for KV7.4/KV7.5 α-subunit co-localization were uniformly detected 
through the DSM cell periphery, suggesting plasmalemmal expression of heteromeric 
KV7.4/KV7.5 channels (Fig. 4.12). These findings, which are consistent with studies on 
rodent vasculature [18] and provide strong evidence confirming heteromeric KV7.4/KV7.5 
channel expression in DSM cells. While heteromeric KV7.4/KV7.5 channels are potently 
activated by ML213 pharmacological activation, it has not yet been reported whether 
heteromeric KV7.2/KV7.3 channels or other KV7.2-containing channels, are ML213-
sensitive. Albeit, the potential activation of KV7.2/KV7.3 channels, for example, by ML213 
would presumably be mediated by the KV7.2 channel subunit as KV7.3 channel subtypes 
are insensitive to ML213. 
In addition, further studies to elucidate the precise stoichiometry of KV7 channels 
and their associations with β-regulatory subunits (KCNE1-5) will be required to further 
understand the potential ML213 targets in DSM. Indeed, a recent study in rodent arterial 
myocytes demonstrated KCNE4 co-localization with KV7.4 and KV7.5 channels, 
respectively [59]. Also, co-expression of KCNE4 with KV7.4 channels was found to 
increase KV7.4 channel expression and current amplitudes [59]. Moreover, a report from 
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bovine DSM suggests KV7.4 channel subtypes as the most abundantly expressed; findings 
consistent with emerging studies in humans demonstrating KV7.4 mRNA expression as the 
primary KV7 channel expressed in DSM [9, 60]. A separate group reported KV7.5 channel 
mRNA expression as the most highly expressed KV7 channel subtype in human DSM [61]. 
Although ML213 and ICA-069673 activate KV7.2 channels, their differential selectivity 
among KV7.4 and KV7.5-containing channels demonstrates the capacity for subtype-
specific pharmacological targeting. 
As our in situ PLA experiments provided decisive evidence confirming the 
expression of heteromeric KV7.4/KV7.5 channel subtypes in DSM (Fig. 4.12), these 
channels may be among the key pharmacological targets for ML213. Albeit, homomeric 
KV7.4 and KV7.5 channel subtypes may also be critically involved as a previous report 
revealed ML213 as equally potent among KV7.4 and KV7.5-containing channels [31]. 
Based on our novel findings regarding KV7 channel conformations in DSM in conjunction 
with our recent electrophysiological studies of ML213, our data suggests key roles for 
KV7.4- and KV7.5-containing channels, including KV7.4/KV7.5 heteromers, in mediating 
the effects of ML213 in DSM. The ability to fine-tune KV7 channel pharmacological 
modulators to exhibit improved selectivity between KV7.4, KV7.5, and KV7.4/KV7.5 
channels, may represent a substantial breakthrough in the development of novel and 
efficacious therapeutic modalities for lower urinary tract dysfunction.  
In conclusion, our study demonstrates that ML213-sensitive KV7.4-and KV7.5-
containing channels are essential regulators of DSM excitability and contractility. KV7 
channel activation by the novel activator ML213 leads to the activation of KV7 currents, 
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hyperpolarization of the membrane potential, a decrease in global intracellular Ca2+ 
concentration, and the attenuation of DSM contractility.  
 
 
Figure 4.12. PLA shows that KV7.4/KV7.5 heteromeric channels are expressed in 
isolated guinea pig DSM cells. Images of a freshly-isolated DSM cell stained with the 
combination of anti-KV7.4 and anti-KV7.5 channel antibodies (upper panels). PLA 
fluorescent signals are shown in red. No PLA fluorescent signals were observed when the 
anti-KV7.4 antibody was co-incubated with the anti-IP3R antibody (lower panels). An 
orthogonal cross-section image of the DSM cell displaying PLA signals was obtained 
following z-stack scans collected along the viewing plane indicated by the dashed (- - -) 
lines and is represented directly below the top right panel. BF, bright field; DAPI, 4′,6-
Diamidine-2′-phenylindole dihydrochloride (nuclear staining shown in blue). 
 





CONDITION AMPLITUDE MUSCLE FORCE DURATION FREQUENCY n/N
Spontaneous Phasic Contractions 
1.1 (0.5-2.4) µM; 
95.6 ± 4.4%
0.7 (0.2-2.8) µM; 
96.8 ± 3.2%
1.6 (0.8-2.9) µM; 
91.6 ± 8.41%
3.9 (0.8-20.3) µM; 
85.4 ± 14.6%
6/6
KCl (20 mM)-Induced Contractions
2.7 (1.4-5.1) µM; 
99.2 ± 0.8%
2.5 (1.2-5.3) µM; 
99.1 ± 0.9%
3.9 (1.9-8.2) µM; 
90.3 ± 9.7%
n/a; 87.6 ± 8.2% 7/7
CCh (0.1 µM)-Induced Contractions  
3.5 (1.9-6.4) µM; 
100% inhibition
2.1 (1.1-3.9) µM; 
100% inhibition
3.0 (1.8-5.3) µM; 
99.7 ± 0.29%
n/a; 100% inhibition 6/6
CCh (1 µM)-Induced Contractions  
6.2 (1.2-30.7) µM; 
84 ± 9.1%
n/a; 92.1  ± 4.2% n/a; 68 ± 9.5% n/a; 47.1 ± 15.4% 6/6
10-Hz EFS-Induced Contractions
2.2 (1.3-3.7) µM; 
83.6 ± 7.6%
2.3 (1.3-4.1) µM; 
83.9 ± 8.2%
n/a; 32.78 ± 13.5% n/a 7/6
20-Hz EFS-Induced Contractions
5.1 (3.1-8.2) µM; 
86.9 ± 6.4%
4.7 (2.7-8.1) µM;  
89.1 ± 6.0%
n/a; 37.46 ± 9.3% n/a 6/6
69 
CHAPTER 5
PHYSIOLOGICAL ROLES OF VOLTAGE-GATED KV7.4/KV7.5 CHANNELS IN 
HUMAN DETRUSOR SMOOTH MUSCLE EXCITABILITY AND CONTRACTILITY 
ABSTRACT 
Emerging research efforts have established voltage-gated KV7 channels (KV7.1-
KV7.5) as key regulators of detrusor smooth muscle (DSM) function; however, essential 
information regarding KV7 channel expression, tetrameric conformations, and 
physiological roles remain to be explored at cellular and tissue levels in human DSM. We 
used RT-PCR, , Western blot, immunocytochemistry, in situ proximity ligation assays 
(PLA), ratiometric fluorescence Ca2+ imaging, isometric DSM tension recordings, and 
perforated patch-clamp electrophysiology using freshly-isolated human DSM strips and 
cells. Human DSM tissues were collected from ## donors undergoing routine open bladder 
surgeries. RT-PCR detected mRNA transcripts for KV7 channel subtypes in human DSM 
tissue and isolated cells. Western blot analysis and immunocytochemistry further 
demonstrated KV7 channel protein expression in DSM tissue and isolated cells, 
respectively. In situ PLA experiments identified co-localization of KV7.4 and KV7.5 
channel subunits, suggesting expression of heteromeric KV7.4/KV7.5 channel subtypes in 
human DSM cells. The KV7 channel activator, retigabine, decreased global Ca
2+ 
concentrations in DSM isolated strips, while the KV7 channel inhibitor XE991 increased 
global Ca2+ concentrations. Retigabine decreased spontaneous phasic and nerve-evoked 
contractions in DSM isolated strips, while the KV7 channel inhibitor XE991 increased 
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spontaneous phasic and nerve-evoked contractions in DSM isolated strips. Retigabine-
induced DSM relaxation was attenuated in the presence of XE991. The KV7.2/KV7.3 
channel activator ICA-069673 and KV7.1 activator L-364,373 also inhibited spontaneous 
phasic contractions. In voltage-clamp mode of the perforated patch-clamp technique, 
retigabine (10 µM) caused a significant increase in the amplitude of whole cell KV7 
currents, effects reversible by washout or blocked by XE991. Further, retigabine 
hyperpolarized the DSM resting membrane potential, while XE991 caused DSM 
membrane depolarization. This study reveals novel aspects of KV7 channel function and 
molecular composition in human DSM cells and tissues, strongly supporting their potential 
therapeutic utility for treatment of lower urinary tract dysfunction.  
INTRODUCTION 
DSM contraction and relaxation underlies the two main functions of the urinary 
bladder: the storage and release of urine. The excitability of DSM is critically regulated by 
the activity of ion channels, including voltage-gated KV7 channels (KV7.1-KV7.5) [4]. KV7 
channels have a prominent role in regulating the DSM resting membrane potential.  
In contrast to other K+ channels, such as the large-conductance voltage- and Ca2+-activated 
K+ channels, KV7 channels do not have a significant role in the repolarization phase of 
action potentials [47, 57]. As the KV7 channels activate at membrane voltages near -60 
mV, below the threshold for L-type voltage-gated Ca2+ channel activation, these channels 
are critically involved in establishing the resting membrane potential [4, 62].  
KV7 channels attain vast heterogeneity as their five pore-forming α-subunits form 
distinct homo- or hetero-tetrameric complexes [14, 63]. Further, KV7 channels associate 
with KCNE-encoded β-regulatory subunits (KCNE1-KCNE5), which may alter KV7 
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channel biophysical properties including subcellular localization, pharmacology, and 
selectivity [14-16, 40, 64]. In neurons, KV7 channel currents were initially characterized as 
“M-currents” [65], preceding the determination that KV7.2/KV7.3 channels were the 
molecular correlate of this current [66]. Also, early studies in the heart revealed the key 
role of the KV7.1/KCNE1 channels in the cardiac delayed rectifier K
+ (IKs) current [46]. 
Nonetheless, based on the emergence of commercially available KV7 channel 
pharmacological modulators, physiological roles for KV7 channels in other tissues, 
including smooth muscle, is becoming apparent [14, 21, 40, 64, 67-69].  
In DSM, KV7 channel functional roles, including in studies from our laboratory [7, 
42], have recently been identified in the guinea pig [7, 8, 42], pig [28]; and rat (Rode, 2010, 
20385123), where the KV7 channel activator retigabine was shown to have pronounced 
effects in reducing DSM contractility [34]. This may elude to the increased micturition 
volume and voiding intervals observed in rats subjected to acute retigabine exposure in 
vivo [26, 28, 34].  More relevant, clinical evidence has proven retigabine to be associated 
with the increased occurrence of urinary retention [70]. As the mechanism of action of 
retigabine is via the activation of KV7 channels, its collateral side effect of urinary retention 
is a significant observation that should be explored scientifically and in the context of 
overall urinary bladder function and OAB medicinal treatment.  
As important functional roles for KV7 channels in DSM function has been 
established in experimental animals, it is of key interest to ascertain the translation 
implications of these findings to humans. Indeed, the clinical effects of retigabine on 
urinary bladder function are noteworthy, albeit evidence of KV7 channel expression and 
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function in human DSM remains largely unexplored as documented by two similar tissue-
level studies in human DSM [9, 44]. 
In this study, we used RT-PCR, qPCR, Western blot, immunocytochemistry, and 
in situ proximity ligation assays (PLA) to determine the mRNA and protein expression of 
KV7 channels and the identify of which KV7 channel α-subunits assemble to form 
functional tetramers. Further, we conducted ratiometric fluorescence Ca2+ imaging, 
isometric DSM tension recordings, and perforated patch-clamp electrophysiology in 
combination with KV7 channel pharmacological modulators to elucidate their 
physiological role in regulating human DSM excitability and contractility. This study 
provides the first molecular, cellular, and tissue-based examination of KV7 channel 
expression and function in human DSM, where these channels serve a key role in overall 
urinary bladder function. 
MATERIALS AND METHODS 
Ethical Approval. All procedures involving the acquisition of human DSM tissues for the 
current studies have been reviewed and approved by the Institutional Review Board of the 
Medical University of South Carolina (protocol number Pro00045232). 
DSM cell isolation and collection. Human DSM single cells were freshly isolated using a 
combination of papain and collagenase as previously described [32]. Human DSM cells 
were used for electrophysiological experiments, PCR, or in situ PLA within 12 h after 
isolation. Intact human DSM strips with urothelium removed were used for single cell 




RT-PCR experiments were conducted on freshly-isolated human DSM tissues and cells as 
previously described [32]. 
Western blot and Immunocytochemistry  
Western blot and immunocytochemical experiments on human DSM tissues and freshly-
isolated cells, respectively, were conducted as previously described [32].  
In situ Proximity Ligation Assay. In Situ PLA was performed on freshly-isolated human 
DSM cells using the Duolink In Situ Proximity Ligation Assay kit (Thermo Fisher 
Scientific, Waltham, MA, USA) according to the manufacturer’s instructions. DSM cells 
underwent fixation in 2% paraformaldehyde (10 min, 37°C) followed by two 15-min 
washes in PBS. DSM cells were then blocked in Duolink blocking solution (30 min, 37°C). 
Subsequently, isolated DSM cells were incubated with anti-rabbit KV7.#/anti-goat KV7.# 
antibodies or anti-goat KV7.#/anti-rabbit KV7.# antibodies, respectively, in Duolink 
antibody diluent solution overnight at 4°C, followed by 2 x 5 min washes in Duolink 1x 
Wash Buffer A solution. DSM cells were then incubated with the Duolink PLA probe anti-
rabbit MINUS and anti-goat PLUS oligonucleotide-conjugated secondary antibodies (1 h, 
37°C), followed by 2 x 5 min washes in Duolink 1x wash buffer A solution. DSM cells 
were then incubated in ligase-ligation solution (30 min, 37°C), which hybridizes the two 
PLA MINUS and PLUS probes when in close proximity (<40 nm). Following ligation, 
DSM cells were washed 2 x 2 min in Duolink 1x wash buffer A solution. Finally, DSM 
cells were incubated in amplification-polymerase solution (100 min, 37°C) containing 
nucleotides and fluorescently-labelled oligonucleotides. The oligonucleotide arm of one 
PLA probe is a primer for rolling-circle amplification. The fluorescently-labeled 
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oligonucleotides hybridize to the rolling-circle amplification product thus permitting 
detection. Following amplification, DSM cells were washed 2 x 10 min in 1x wash buffer 
B and then a 1 min wash in 0.01x wash buffer B. Slides were then mounted using minimal 
volume of Duolink In Situ mounting medium with 4',6-Diamidino-2-Phenylindole, 
Dihydrochloride (DAPI). PLA signals (Duolink In Situ Detection Reagents Orange 
(λexcitation/emission= 554/576 nm)) were detected using a laser scanning LSM 700 confocal 
microscope (Carl Zeiss, Germany) with a 63x oil immersion objective.  
Isometric DSM tension recordings. Isometric DSM tension recordings were conducted 
as previously described on isolated DSM strips void of urothelium [51]. For experiments 
on spontaneous phasic contractions, the isolated DSM isolated strips were pretreated 
tetrodotoxin (TTX, 1 µM), a neuronal voltage-gated Na+ channel blocker, before the 
application of KV7 channel pharmacological modulators. Electric field stimulation (EFS)-
induced DSM contractions were stimulated with a PHM-152I programmable stimulator 
(Med Associates, Inc., Georgia, VT, USA) in the absence of TTX. 0.5-50 Hz EFS-induced 
contractions were stimulated at 3 min intervals over a wide range of frequencies (0.5, 2.0, 
3.5, 5, 7.5, 10, 12.5, 15, 20, 30, 40, 50 Hz) in the absence (control) and then in the presence 
of either retigabine (10 µM) or XE991 (10 µM).  
Ratiometric Fluorescence Ca2+ imaging. Global intracellular Ca2+ concentrations of 
isolated human DSM strips were measured using the ratiometric fluorescence Ca2+ probe 
fura-2 AM as previously described [32]. 
Solutions and drugs. Ca2+-free dissection solution contained the following (in mM): 80 
monosodium glutamate; 55 NaCl; 6 KCl; 10 glucose; 10 4-(2-hydroxyethyl) piperazine-1-
ethanesulfonic acid (HEPES); 2 MgCl2; NaOH was used to attain pH 7.3. Ca
2+-containing 
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physiological saline solution contained the following (in mM): 119 NaCl; 4.7 KCl; 24 
NaHCO3; 1.2 KH2PO4; 2.5 CaCl2; 1.2 MgSO4; 11 glucose; that was aerated with 95% 
O2/5% CO2 to attain pH 7.4. Physiological bath solution utilized for patch-clamp 
experiments was composed of the following (in mM): 134 NaCl; 6 KCl; 1 MgCl2; 2 CaCl2; 
10 glucose; 10 HEPES; and NaOH was used to obtain pH 7.4. The patch-pipette solution 
contained (in mM): 110 potassium aspartate; 30 KCl; 10 NaCl; 1 MgCl2; 10 HEPES; 0.05 
ethylene glycol-bis(2-aminoethylether)-N,N,N',N'-tetraacetic acid (EGTA); NaOH was 
used to adjust the pH to 7.2. Amphotericin-B stock solution was prepared daily in dimethyl 
sulfoxide (DMSO) and was included in the pipette solution (200-300 μg/ml) before the 
experiment and was replaced every 1-2 h. ML213, TTX citrate, and XE991 were purchased 
from Tocris Bioscience (Minneapolis, MN). Fura-2 AM was purchased from Life 
Technologies (Cat No.: F1221, Carlsbad, CA). ML213 and Fura-2 AM were dissolved in 
DMSO, while XE991 and TTX citrate were dissolved in double-distilled water. All other 
chemicals were obtained from Fisher Scientific (Waltham, MA), Sigma-Aldrich, or 
Worthington Biochemical Corp. (Lakewood, NJ). 
RESULTS 
KV7 channel subtypes are expressed at the mRNA level in freshly-isolated human 
DSM cells and tissues. To elucidate KV7 channel mRNA expression in human DSM, we 
began by conducting conventional RT-PCR using human DSM tissues. At the tissue-level 
in human DSM, we detected mRNA transcripts for all KV7 channel subtypes except KV7.2 
(Figure 5.1). KV7 channels are known to be expressed in non-DSM tissues including 
neurons and instersitial cells. Therefore, we sought to clarify KV7 channel mRNA 
expression by conducting parallel RT-PCR experiments using RNA isolated specifically 
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from human DSM single cells. At the cellular level in DSM, we identified transcripts for 
KV7.4 and KV7.5 subunits.  
KV7 channel subtypes are expressed at the protein-level in human DSM tissues and 
freshly-isolated cells. To confirm KV7 channel protein expression in human DSM tissues 
and freshly-isolated cells, we utilized Western blot analysis and immunocytochemistry 
with confocal microscopy. As shown in Figure 5.2, Western blot data identified protein 
expression for all KV7 channel subtypes except KV7.2 in human DSM tissue. 
Chemiluminescent bands were not observed when KV7.1 and KV7.3-KV7.5 channel 
antibodies were incubated in the presence of their competing peptides (+CP), respectively. 
Again, as KV7 channels are expressed in non-DSM tissues within the detrusor layer, we 
sought to confirm KV7 channel protein expression directly in freshly-isolated DSM cells 
using immunocytochemistry with confocal microscopy (Figure 5.3).  
KV7.4 and KV7.5 channel α-subunits associate to form heterotetrameric KV7.4/KV7.5 
channel subtypes in freshly-isolated DSM cells. KV7 channel subunits (KV7.1-KV7.5) 
differentially associate to form functional tetrameric channels with distinct biophysical 
properties [14]. Using in situ PLA, we sought to determine whether KV7.4 and KV7.5 
channels, the KV7 channel subtypes expressed in isolated DSM cells (Figure 1), form 
heteromeric channels in freshly-isolated DSM cells. In situ PLA demonstrated KV7.4 and 
KV7.5 channel subunits associate to form heteromeric KV7.4/KV7.5 channels in isolated 
human DSM cells. As shown in Figure 5.4, in situ PLA experiments demonstrated the co-
localization of KV7.4 and KV7.5, channel α-subunits within 40 nm and within the vicinity 
of the DSM cell membrane. Primary antibodies against the IP3R, which would not be 




Figure 5.1. KV7 channels mRNA transcripts are present in freshly-isolated human 
DSM cells and tissues. KV7 channel subtype mRNA detection in human DSM whole 
tissues and freshly-isolated single cells. RT-PCR experiments detected mRNA for all KV7 
channel subtypes except KV7.2 in whole human DSM tissues. Further experiments using 
freshly-isolated human DSM single cells revealed KV7.4 and KV7.5 channels are the only 
subtypes present at the mRNA level in human DSM. No bands were observed in the 
absence of reverse transcriptase (-RT). Results were confirmed in experiments from at least 




Figure 5.2. Western blot analyses demonstrated protein expression for KV7.1 and 
KV7.4-KV7.5 channel subtypes in human DSM. Western blot experiments demonstrate 
protein expression for KV7.1-5 channel subtypes in human DSM. A) KV7.1, B) no KV7.2, 
C) KV7.3, D) KV7.4 and E) KV7.5 channel subtypes were detected using KV7 channel 
subtype-specific antibodies. Incubation of the KV7 channel primary antibodies with each 
respective competing peptide (+CP) eliminated protein detection thereby confirming 
antibody selectivity. These results were verified in at least three human DSM tissues 




Figure 5.3. KV7.1 and KV7.4-KV7.5 channel subtypes are expressed at the protein level 
in freshly-isolated human DSM cells. Confocal images from immunocytochemical 
experiments demonstrate the expression KV7.1- KV7.5 (A-E) channel subunits in freshly-
isolated human DSM cells. Red staining indicates detection of KV7.1- KV7.5 channel 
subunits, respectively. Blue staining indicates the nucleus. The anti-actin, α-smooth muscle 
probe is shown in green (top right). The overlaid images for KV7.1- KV7.5 channels with 
anti-actin, α-smooth muscle probe and DAPI nuclear stain is shown at the bottom right, 
respectively. Co-localization of each KV7channel subtypes with the anti-actin, α-smooth 
muscle is indicated by the yellow color in the merged images, respectively. Data were 
confirmed in multiple experiments using DSM tissues from at least 3 guinea pigs. Images 
were acquired with a Zeiss LSM 700 confocal microscope using a 63X oil objective. 
control. Co-incubation of the KV7.4 channel primary antibody with the primary antibody 
of the IP3Rs yielded no PLA fluorescent signal (Fig. 5.4). These combined results suggest 
that KV7.4 and KV7.5 channel subunits assemble to form heteromeric KV7.4/KV7.5 channel 
subtypes in DSM cells.  
 
KV7 channels regulate spontaneous phasic contractions in human DSM isolated 
strips. To elucidate whether KV7 channel pharmacological modulation of the KV7 channels 
corresponds to functional changes in human DSM contractility, we conducted isometric 
tension recordings on human DSM isolated strips. As demonstrated by Fig. 5.5, KV7 
79 
channel pharmacological activation with retigabine (10 µM) decreased spontaneous phasic 
contractions in human DSM isolated strips from control (non-OAB) and OAB patients 
(n=9, N=5 for Control non-OAB, Fig. 5.5; n=5, N=5 for OAB, Fig. 5.5; *P<0.05). There 
was no statistically significant difference in the inhibitory effects of retigabine on 
spontaneous phasic contraction parameters in control versus OAB patients. The KV7 
channel inhibitor XE991 (10 uM) increased spontaneous phasic contractions of DSM 
isolated strips (n=12, N=7; *P<0.05; Figure 5.6, A-B). In the presence of XE991 (10 uM), 
retigabine had no significant inhibitory effects on spontaneous phasic contractions (n=5, 
N=4; *P<0.05; Figure 5.6, C-D), confirming the selectivity of retigabine for the KV7 
channel subtypes. There was a statistically significant difference between the inhibitory 
effects of retigabine in the absence versus presence of XE991, confirming the selectivity 
of retigabine for KV7 channel subtypes.  
KV7 channels regulate nerve-evoked contractions in human DSM isolated strips. We 
next aimed to elucidate the role of the KV7 channels in regulating nerve-evoked 
contractions in human DSM isolated strips using electrical field stimulation (EFS) 
contractions induced over a range of EFS frequencies (0.5-50 Hz) in combination with KV7 
channel pharmacological modulators. Retigabine (10 µM) caused a significant decrease in 
the amplitude of 0.5-50 Hz EFS-induced contractions (n=7, N=4; P<0.05; Figure 5.7, D-
E). KV7 channel inhibition with XE991 decreased 0.5-50 Hz EFS-induced contractions 
(n=6, N=5; P<0.05; Figure 5.7, A-B). These results poise the KV7 channels as important 
regulators of nerve-evoked contractions in human DSM isolated strips.  
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OVERALL CONCLUSIONS  
This study examined the expression and physiological roles of voltage-gated KV7 channels 
in human DSM excitability and contractility. PCR experiments detected mRNA transcripts 
for KV7.1 and KV7.3-KV7.5 channel subtypes in DSM tissue, with only KV7.4-KV7.5 
channel subtypes at the cellular level in human DSM. Western blot analysis confirmed 
KV7.1 and KV7.3-KV7.5 channel protein expression in human DSM tissues. However, 
immunocytochemistry revealed only KV7.4 and KV7.5 channel subtype protein expression 
was present in freshly-isolated human DSM cells. Further, using in situ PLA, we confirmed 
the molecular interaction between KV7.4 and KV7.5 channel α-subunits, suggesting 
heteromeric KV7.4/KV7.5 channel subtype expression at the cellular level in human DSM 
cells. Retigabine decreased spontaneous and nerve-evoked contractions, decreased global 
Ca2+ concentrations, hyperpolarized the DSM cell membrane potential, and enhanced 
whole cell KV7 currents in DSM cells. XE991 increased spontaneous and nerve-evoked 
DSM contractions, increased global Ca2+ concentrations, depolarized the DSM cell 
membrane potential, and blocked retigabine-induced inhibition of DSM contractions.  
KV7 channel expression and functional roles have been emerging in recent years in reports 
on experimental animals. However, studies of KV7 channel expression and function in 
human DSM are currently lacking and represented by only two superficial and tissue-level 
studies in human DSM [9, 44]. One of these studies reported the detection of mRNA 
transcripts for all KV7 channel subtypes except KV7.2 at the tissue level in human DSM 
[9]. Consistently, a second report in human DSM utilizing qPCR reported KV7 channel 
subtype expression in rank order: KV7.4>KV7.5>KV7.3>KV7.1, with minimal or no 
detection of KV7.2 channel subtypes [44].   
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Figure 5.4. In situ PLA detection of KV7.4/KV7.5 heteromeric channels expressed in 
isolated guinea pig DSM cells. Images of a freshly-isolated DSM cell stained with the 
combination of anti-KV7.4 and anti-KV7.5 channel antibodies (upper panels). PLA 
fluorescent signals are shown in red. No PLA fluorescent signals were observed when the 
anti-KV7.4 antibody was co-incubated with the anti-IP3R antibody (lower panels). An 
orthogonal cross-section image of the DSM cell displaying PLA signals was obtained 
following z-stack scans collected along the viewing plane indicated by the dashed (- - -) 
lines and is represented directly below the top right panel. BF, bright field; DAPI, 4′,6-
Diamidine-2′-phenylindole dihydrochloride (nuclear staining shown in blue).  
 
Protein expression for KV7.1, KV7.4, and KV7.5 channel subtypes was further 
reported using Western blot analysis [44]. However, these experiments by Bientinesi et al., 
which excluded KV7.3 channel subtypes, did not include appropriate positive or negative 
controls [44], which raise questions as to the validity of the data. Minimal or no expression 
of KV7.2 channel mRNA has also been reported in several non-DSM tissue types across 
multiple species including the murine and rat airway [20, 71], rat mesenteric arteries [72], 
human airway smooth muscle [17], and in human arteries [22]. 
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Figure 5.5. Retigabine, a KV7.2-KV7.5 channel subtype activator inhibited 
spontaneous phasic contractions in human DSM control and OAB patients. 
Retigabine, a KV7.2- KV7.5 channel subtype activator, inhibited spontaneous phasic 
contractions in human DSM. A) An original isometric DSM tension recording 
demonstrating the inhibition of spontaneous phasic contractions by retigabine (10 µM). B) 
Summarized data for the inhibitory effects of retigabine (10 µM) on human DSM 
contraction parameters including contraction amplitude, muscle force, tone, contraction 
duration, and frequency (n=9, N=5; ***P<0.001 for each). C) An original isometric DSM 
tension recording demonstrating the inhibition of spontaneous phasic contractions by 
retigabine (10 µM) in an OAB patient. D) Summarized data for the inhibitory effects of 
retigabine (10 µM) on human DSM contraction parameters in control versus OAB patients 
(n=3, N=3).  
 
Interestingly, the expression of KV7.4 and KV7.5 channel subtype is consistent with 
emerging reports of KV7 channel expression in smooth muscle tissues [22, 40, 73]. 
Nonetheless, conflicting reports exist in the literature concerning which KV7 channel 
subtype (i.e. KV7.4 or KV7.5) is most highly expressed in human DSM. The most recent of 
these two reports indicated KV7.4 channels were most highly expressed, while a separate 
group demonstrated KV7.5 channel mRNA as the most highly expressed KV7 channel 
subtype in human DSM [61, 74].While KV7 channel mRNA expression has been emerging, 





Figure 5.6. XE991, a KV7.1-KV7.5 channel subtype inhibitor increased spontaneous 
phasic contractions and blocked retigabine-induced relaxation in human DSM 
isolated strips. XE991, a KV7.1-KV7.5 channel subtype inhibitor increased spontaneous 
phasic contractions in human DSM. A) An original isometric DSM tension recording 
demonstrating the augmented spontaneous phasic contractions induced by XE991 (10 µM). 
B) Summarized data for the stimulatory effects of XE991 (10 µM) on human DSM 
contraction parameters including contraction amplitude, muscle force, tone, contraction 
duration, and frequency (n=12, N=7; *P<0.05 and **P<0.01).  C) An original isometric 
tension recording demonstrating the effect of retigabine (10 µM) upon human DSM 
spontaneous phasic contractions subject to pretreatment with XE991 (10 µM). D) 
Summarized data comparing the effects of retigabine (10 µM) in the absence or presence 
of XE991 (10 µM) upon human DSM contraction parameters including contraction 
amplitude, muscle force, tone, contraction duration, and frequency (n=5-9, N=4-5; 
**P<0.01 and ***P<0.001).  
 
Our current data reveals the expression of KV7.4 and KV7.5 channel subtypes at the 
mRNA and protein levels (Figure 5.1-5.4). This could be very significant as this 
demonstrates the potential pharmacological efficacy of future selective KV7.4/KV7.5 
channel activators as effective treatments for OAB, while KV7.2/KV7.3 selective 
modulators may prove better for the treatment of neurological conditions. Thus, this may 




Figure 5.7. Retigabine and XE991 attenuated EFS-induced contractions in human 
DSM. Original isometric tension recording illustrating 3.5-50 Hz EFS-induced 
contractions before (A) and after (B) the addition of retigabine (10 µM). C) Frequency-
response curves illustrating the inhibitory effects of retigabine on the amplitude of 3.5-50 
Hz EFS-induced contractions (n=7, N=4; *P<0.05, **P<0.01, ***P<0.001). D) Original 
isometric tension recording illustrating 3.5-50 Hz EFS-induced contractions before and 
after (E) the addition of XE991 (10 µM). F) Frequency-response curves illustrating the 
inhibitory effects of retigabine on the amplitude of 3.5-50 Hz EFS-induced contractions 
(n=7, N=4; *P<0.05, **P<0.01, ***P<0.001). 
 



















Table 5.1 Human KCNQ Primer Sequences for PCR 
KCNQ1 (180 bp) 
F: 5'-CTGTCTTTGCCATCTCCTTCT-3' 
R: 5'-GCGTCACCTTGTCTTCTACTC-3' 
KCNQ2 (190 bp) 
F: 5'-GGCTTCCTTTGTCTCATCCT-3' 
R: 5'-CTGGACTGCAGGCTCTTAAT-3' 
KCNQ3 (195 bp) 
F: 5'-TCGGGTTCGCCTTTCTAATC -3' 
R: 5'-GTGCCCTTGGTTGGGTAATA-3' 
KCNQ4 (201 bp) 
F: 5'-CCACCCTGTCCCTATTCTTTG-3' 
R: 5'-GAAGCACTGTCTGGGAGTTT-3' 




therefore the beneficial implications of this research is incredibly relevant to public health, 
clinical medicine, and most importantly, quality of life. Based on our data from in situ 
PLA, we provide compelling evidence to confirm the expression of heteromeric 
KV7.4/KV7.5 channel subtypes in human DSM cells (Fig. 12). Therefore, heteromeric 
KV7.4/KV7.5 channel subtypes may be among the key KV7 channel subtypes involved in 
the regulation of DSM function. Although, homomeric KV7.4 and/or KV7.5 channel 
subtypes may also be important for DSM function. Our novel findings concerning the 
cellular and tissue-level expression of the KV7 channel, in conjunction with our functional 
studies of DSM excitability and contractility, our data suggests key physiological roles for 
the KV7 channels in human DSM function, with KV7.4 and KV7.5-containing channels, 
including heteromeric KV7.4/KV7.5 channels, as potentially the upmost of physiological 
relevance.  
Nonetheless, taken together with our previous studies in the guinea pig (Chapters 
3-4), further studies in human DSM will be required using multiple KV7 channel compound 
with improved selectivity to that of retigabine. Further, electrophysiological experiments 
will also prove helpful in human DSM in order to confirm KV7 channel drug effects are 
indeed a result of direct modulation of KV7 current activity. The ability to fine-tune KV7 
channel pharmacological modulators to exhibit improved selectivity between KV7.4, 
KV7.5, and KV7.4/KV7.5 channels, may represent a substantial breakthrough in the 
development of novel and efficacious therapeutic modalities for lower urinary tract 
dysfunction. These combined studies may help to provide a rationale for further studies in 




8REGULATION OF TRANSIENT RECEPTOR POTENTIAL MELASTATIN 4 CHANNEL 
BY SARCOPLASMIC RETICULUM INOSITOL TRIPHOSPHATE RECEPTORS: ROLE 
IN HUMAN DETRUSOR SMOOTH MUSCLE FUNCTION 
ABSTRACT 
We recently reported key physiological roles for Ca2+-activated transient receptor potential 
melastatin 4 (TRPM4) channels in detrusor smooth muscle (DSM). However, the Ca2+-
signaling mechanisms governing TRPM4 channel activity in human DSM cells are 
unexplored. As the TRPM4 channels are activated by Ca2+, inositol 1,4,5-trisphosphate 
receptor (IP3R)-mediated Ca
2+ release from the sarcoplasmic reticulum represents a 
potential Ca2+ source for TRPM4 channel activation. We used clinically-characterized 
human DSM tissues to investigate the molecular and functional interactions of the IP3Rs 
and TRPM4 channels. With in situ proximity ligation assay (PLA) and perforated patch-
clamp electrophysiology, we tested the hypothesis that TRPM4 channels are tightly 
associated with the IP3Rs and are activated by IP3R-mediated Ca
2+ release in human DSM. 
With in situ PLA, we demonstrated co-localization of the TRPM4 channels and IP3Rs in 
human DSM cells. As the TRPM4 channels and IP3Rs must be located within close 
apposition to functionally interact, these findings support the concept of a potential Ca2+-
mediated TRPM4-IP3R regulatory mechanism. To investigate IP3R regulation of TRPM4 
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channel activity, we sought to determine the consequences of IP3R pharmacological 
inhibition on TRPM4 channel-mediated transient inward cation currents (TICCs). In 
freshly-isolated human DSM cells, blocking the IP3Rs with the selective IP3R inhibitor 
xestospongin-C significantly decreased TICCs. The data suggest that IP3Rs have a key role 
in mediating the Ca2+-dependent activation of TRPM4 channels in human DSM. The study 
provides novel insight into the molecular and cellular mechanisms regulating TRPM4 
channels by revealing that TRPM4 channels and IP3Rs are spatially and functionally 
coupled in human DSM.  
INTRODUCTION 
The functions of the urinary bladder – the principle organ charged with the storage 
and periodic release of urine – are mediated by the activity of detrusor smooth muscle 
(DSM). In DSM cells, it is well-established that Ca2+ influx through L-type voltage-gated 
Ca2+ channels underlies the depolarization phase of spontaneous action potentials whilst 
the large-conductance voltage- and Ca2+-activated K+ (BK) channels, in addition to other 
voltage-gated KV channels, work in opposition to L-type voltage-gated Ca
2+ channel 
activity to promote membrane hyperpolarization[4, 57, 76, 77]. Albeit these mechanisms 
have been known for many years in DSM, recent studies from our group have identified 
an important role for an additional Ca2+-sensitive cationic conductance regulating DSM 
function in rodents and humans[33, 78-80]. Indeed, Ca2+-activated monovalent cation 
channels known as the transient receptor potential (TRP) melastatin 4 (TRPM4) channels 
are functionally expressed in rat, guinea pig, and human DSM[33, 78-80]. 
Of the 28 members that constitute the TRP channel superfamily, TRPM4 channels, 
in addition to TRPM5, are the only TRP channel members selective for monovalent cations 
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(K+ and Na+)[81, 82]. TRPM4 channel functional roles in excitable cells and tissues, 
including rodent[33, 79, 80] and human DSM[33, 78-80], have begun to emerge in recent 
years following studies using the novel and selective TRMP4 channel inhibitor, 9-
phenanthrol[33, 79, 80, 83-85]. We recently provided the first detailed study demonstrating 
the expression and key functional roles for TRPM4 channels in human DSM excitability 
and contractility using the selective TRPM4 channel inhibitor 9-phenanthrol[78]. Our 
novel study was the central topic of an editorial focus in the American Journal of 
Physiology – Cell Physiology[86], which highlighted the attractiveness of the TRPM4 
channels as potential novel targets for the pharmacological control of the urinary bladder. 
Under pathophysiological conditions, DSM dysfunction is associated with some forms of 
overactive bladder[12]. The TRPM4 channels, in addition to the cellular mechanisms 
regulating their activity, represent an exciting and novel therapeutic approach to the 
treatment of various bladder disorders and the collateral effects these conditions inflict on 
patient quality of life. Nonetheless, significant work still remains to ascertain the cellular 
mechanisms regulating TRPM4 channel activity in human DSM function to further 
validate their potential therapeutic role for bladder disorders.  
It has been suggested that Ca2+ release from the sarcoplasmic reticulum (SR) 
inositol 1,4,5-trisphosphate (IP3) receptors (IP3Rs) may constitute a primary Ca
2+ source 
for TRPM4 channel activation[87]. The concept of IP3R-mediated Ca
2+ release serving as 
critically important Ca2+ source for TRPM4 channel activation, as opposed to Ca2+ influx 
through L-type voltage-gated Ca2+ channels, was supported by the observation that 
removal of extracellular Ca2+ had no acute effects on TRPM4 channel activity[87]. 
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Whether this TRPM4-IP3R regulatory mechanism exists in human DSM, however, is 
completely unknown. 
Therefore, the current study sought to investigate the molecular and functional 
interaction of the TRPM4 channels and IP3Rs in human DSM. This was achieved via a 
combined experimental approach using in situ proximity ligation assays (PLA) and 
perforated patch-clamp electrophysiology in combination with pharmacological tools. This 
study reveals the novel mechanism whereby SR IP3Rs regulate the excitability of human 
DSM through molecular and functional interactions with TRPM4 channels. 
MATERIALS AND METHODS 
Human DSM tissue acquisition. Human DSM tissues were acquired from donor patients 
undergoing routine open bladder surgeries as previously described[78, 88, 89]. All 
procedures attendant upon the collection of human DSM tissues have been reviewed and 
approved by the Institutional Review Board of the Medical University of South Carolina 
(protocol number Pro00045232). 6 Caucasian patients (3 men and 3 women; average age 
64.5±11.2 years) without preoperative histories of overactive bladder and American 
Urological Association symptom scores <8 were used for this study. Following surgeries, 
human DSM tissues were stored on ice in a container containing HEPES-buffered 
dissection solution (see Solutions and Drugs) for immediate transport to the laboratory for 
DSM cell isolation.  
DSM cell isolation. Human DSM single cells were enzymatically isolated using a 
combination of papain and collagenase as previously described[78, 88, 89]. Freshly-
isolated DSM cells were used for in situ PLA or electrophysiological experiments within 
12 h following isolation.  
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In situ Proximity Ligation Assay (PLA). In situ PLA was performed on freshly-isolated 
DSM cells using the Duolink® in situ orange starter kit goat/rabbit (Cat. No: DUO92106, 
Sigma-Aldrich, St. Louis, MO) according to the manufacturer’s instructions. DSM cells 
underwent fixation in 2% paraformaldehyde (10 min, 37°C) followed by two 15-min 
washes in phosphate buffered saline. DSM cells were blocked in Duolink blocking solution 
(30 min, 37°C). Subsequently, DSM cells were incubated with the anti-rabbit IP3R and 
goat anti-TRPM4 channel antibodies (Santa Cruz Biotechnology, Dallas, TX; catalog 
numbers SC-27540 TRPM4; SC-28614 IP3R), respectively, in Duolink antibody diluent 
solution overnight at 4°C, followed by 2x5 min washes in Duolink 1x wash buffer A 
solution. DSM cells were then incubated with the Duolink PLA probe anti-rabbit MINUS 
and anti-goat PLUS oligonucleotide-conjugated secondary antibodies (1 h, 37°C), 
followed by 2x5 min washes in Duolink 1x wash buffer A solution. DSM cells then 
underwent incubation in ligase-ligation solution (30 min, 37°C), which hybridizes the two 
PLA MINUS and PLUS probes when in close proximity (<40 nm). Following ligation, 
DSM cells were washed 2x2-min in Duolink 1x wash buffer A solution. Finally, DSM cells 
were incubated in amplification-polymerase solution (100 min, 37°C) containing 
nucleotides and fluorescently-labelled oligonucleotides. The oligonucleotide arm of one 
PLA probe is a primer for rolling-circle amplification. The fluorescently-labeled 
oligonucleotides hybridize to the rolling-circle amplification product thus permitting 
detection. Following amplification, DSM cells were washed 2x10 min in 1x wash buffer B 
and then a 1 min wash in 0.01x wash buffer B. Slides were then mounted using minimal 
volume of Duolink in situ mounting medium with 4',6-diamidino-2-phenylindole (DAPI). 
PLA signals (Duolink In Situ Detection Reagents Orange (λexcitation/emission=554/576 nm)) 
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were detected using laser scanning LSM 700 confocal microscope (Carl Zeiss, Germany) 
with a 63x oil immersion objective. 
Patch-clamp electrophysiology. The amphotericin B-perforated whole cell patch-clamp 
technique was used in all of the electrophysiological recordings as previously described[32, 
33, 78, 80]. At the holding potential of -70 mV, the total open channel probability (NPo) of 
TRPM4 channel-mediated transient inward cation currents (TICCs) before and after the 
addition of xestospongin-C was analyzed. A stable recording period of at least 5-10 min 
before and after the addition of xestospongin-C was utilized for analysis with pCLAMP 
version 10.2 software (Molecular Devices, Union City, CA). 
Solutions and drugs. The Ca2+-free dissection solution had the following composition (in 
mM): 80 monosodium glutamate, 55 NaCl, 6 KCl, 2 MgCl2, 10 HEPES, and 10 glucose, 
adjusted to pH 7.3 with NaOH. The extracellular (bath) solution used in the patch-clamp 
experiments in the gap-free mode (both voltage- and current-clamp) contained (in mM): 
134 NaCl, 6 KCl, 1 MgCl2, 2 CaCl2, 10 glucose, and 10 HEPES, pH adjusted to 7.4 with 
NaOH. The patch-clamp pipette solution for these experiments contained (in mM): 110 
potassium aspartate, 30 KCl, 10 NaCl, 1 MgCl2, 10 HEPES, and 0.05 EGTA, pH adjusted 
to 7.2 with NaOH and supplemented with freshly dissolved (every 1–2 h) 200 μg/ml 
amphotericin-B in dimethyl sulfoxide. Bovine serum albumin was obtained from Thermo 
Fisher Scientific (Fair Lawn, NJ). All other compounds were obtained from Sigma-
Aldrich.  
Data analysis and statistics. The TICCs were analyzed as open channel probability (NPo) 
as previously described[78]. Data are summarized as means ± SEM for n (the number of 
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DSM cells) isolated from N (the number of patients). Data were compared using a paired 
Student's t-test. A P value <0.05 was considered statistically significant. 
RESULTS 
TRPM4 channels are colocalized with the IP3Rs in human DSM cells. In order for the 
discrete Ca2+ release events from SR IP3Rs to regulate TRPM4 channel activity in human 
DSM, the IP3Rs and TRPM4 channels must be located within close apposition. To 
determine TRPM4 channel colocalization with IP3Rs, we conducted Duolink in situ PLA 
on freshly-isolated human DSM cells. To elucidate TRPM4/IP3R colocalization, human 
DSM cells were incubated with the anti-TRPM4 goat and anti-IP3R rabbit antibodies, 
respectively. As shown in Fig. 6.1A-B, co-incubation of TRPM4 and IP3R antibodies 
positively confirmed that TRPM4 channels and IP3Rs are located in close proximity (<40 
nm) to the cell membrane as indicated by the bright red fluorescence. Fluorescent detection 
was not observed when the anti-TRPM4 goat antibody was omitted (Fig. 6.1C). As a 
negative control, we utilized a rabbit antibody specific for the voltage-gated KV7.5 channel 
subtype, which is expressed in human DSM[90, 91], but not expected to interact with 
TRPM4 channels. Incubation of human DSM cells with anti-TRPM4 and anti-KV7.5 rabbit 
antibodies, respectively, resulted in no observable fluorescent signal (Fig. 1). Results were 
confirmed in at least three human DSM cells.  
IP3R pharmacological inhibition with xestospongin-C decreases transient inward 
cation current activity in human DSM cells. In non-DSM cells, TRPM4 channels have 
been shown to be regulated by Ca2+ release events originating from the SR IP3Rs[92]. 
Therefore, SR IP3R Ca
2+ release activity may constitute a fundamentally important cellular 
mechanism regulating TRPM4 channel activity in human DSM. To ascertain whether SR 
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IP3Rs potentially regulate TRPM4 channel activity in human DSM, we examined the 
physiological consequences of IP3R pharmacological inhibition on TRPM4 channel-
mediated TICCs. At the holding potential of -70 mV, where BK channel activity is 
negligible[80], pharmacological inhibition of the IP3Rs with the selective inhibitor 
xestospongin-C (1 µM) significantly reduced TICC activity (NPo) from 2.0±1.1 in control 
conditions to 1.3±1.0 in the presence of 1 µM xestospongin-C (n=6, N=4; P<0.05; Fig. 
6.2). These results support the concept that Ca2+ release events from SR IP3Rs are involved 
in the regulation of TRPM4 channel-mediated TICCs in human DSM cells (Fig. 6.3). 
DISCUSSION 
This study sought to determine whether IP3Rs of the SR regulate TRPM4 channel 
activity in human DSM function. This was achieved by elucidating IP3R-TRPM4 channel 
spatial and functional interactions in human DSM by utilizing in situ PLA and perforated 
patch-clamp electrophysiology in combination with the IP3R inhibitor xestospongin-C. In 
situ PLA confirmed co-localization between IP3Rs and TRPM4 channels in human DSM 
isolated cells. Further, IP3R pharmacological inhibition with xestospongin-C led to the 
attenuation of TICCs. This study established the novel finding that TRPM4 channels and 
SR IP3Rs are physically and functionally coupled in the regulation of human DSM 
excitability. 
Several studies from our laboratory have revealed key roles for the TRPM4 
channels in regulating the excitability and contractility of DSM in rodents[33, 79, 80]. 
More recently, we further explored the translational implications of our findings in rodents 
by investigating the physiological roles for the TRPM4 channels in clinically-characterized 
human DSM [78]. As summarized in a recent editorial article in the American Journal of 
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Physiology Cell Physiology[86], our group revealed critical roles for the TRPM4 channels 
in regulating DSM function. TRPM4 channel expression is abundant in human DSM and 
species-related differences in the functional roles of the TRPM4 channels have been 
reported between human and rodents[78]. This previous report by our group provided 
compelling evidence at the cellular level in human DSM demonstrating the TRPM4 
channel inhibitor 9-phenanthrol had a substantially greater inhibitory effect on DSM cell 
excitability in human versus rodent DSM cells[78].  
Utilizing the selective TRPM4 channel inhibitor 9-phenanthrol, we reported that 
the pharmacological inhibition of the TRPM4 channels hyperpolarized the membrane 
potential in human DSM cells and caused inhibition of spontaneous phasic, 
pharmacologically-induced, and nerve-evoked contractions in human DSM isolated 
strips[78]. Among the mechanisms underlying the inhibitory effects of 9-phenanthrol on 
human DSM excitability and contractility includes the attenuation of TICCs[33, 78-80]. 
TICCs are caused by Na+ influx following Ca2+-dependent TRPM4 channel activation 
which, under physiological conditions, functions to enhance DSM cell excitability[78, 93, 
94].  
As TRPM4 channels are activated by Ca2+, it was critically important to determine 
the specific Ca2+-dependent molecular and cellular mechanisms involved in the regulation 
of TRPM4 channel activity. Albeit well-known, there are two key sources for the elevation 
of intracellular Ca2+ concentrations, including: 1) Ca2+ entry through L-type voltage-gated 
Ca2+ channels at the cell membrane, or 2) Ca2+ release events through SR ryanodine 
receptors or IP3Rs[57, 94]. In particular, emerging evidence from non-DSM cell types have 
shown that members of the TRP channel family, including TRPM4, can be activated by 
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intracellular Ca2+ released from SR IP3Rs. IP3R-mediated activation of adjacent TRPM4 
channels, as has been reported in non-DSM cell types[87, 95], would lead to depolarization 
of the cell membrane potential, activation of L-type voltage-gated Ca2+ channels, an 
increase in global intracellular Ca2+ concentrations, and thus the activation of DSM 
contractions. In fact, in cerebral artery myocytes, sustained TRPM4 channel activity was 
shown to be dependent on Ca2+ released from the SR IP3Rs[96]. 
Given the critically important role for the TRPM4 channels in human DSM 
excitability and contractility, we sought to examine whether IP3Rs and TRPM4 channels 
functionally interact to regulate human DSM function. Our results demonstrated that 
xestospongin-C, a selective IP3R inhibitor, significantly decreased TICC activity in human 
DSM cells (Fig. 6.2). These results are consistent with IP3R-dependent regulation of 
TRPM4 channels in human DSM by a similar mechanism as was suggested for cerebral 
artery myocytes. Ca2+ released from the SR IP3Rs are localized and transient events as has 
been demonstrated in murine colonic myocytes and rabbit portal vein myocytes[84, 97]. 
Hence, localized Ca2+ release events for the SR IP3Rs must be in close apposition to the 
plasmalemmal TRPM4 channels in order for IP3R-TRPM4 channel functional coupling. 
Thus, to ascertain the potential co-localization for the TRPM4 channels and IP3Rs, we 
utilized the Duolink in situ PLA technique in combination with TRPM4 channel and IP3R-
specific antibodies. As illustrated by Fig. 6.1, in situ PLA experiments demonstrated the 
co-localization of IP3Rs and TRPM4 channels in freshly-isolated human DSM cells within 
the vicinity of the cell membrane. These results are in contrast to findings from arterial 
myocytes, where IP3R co-localization was confirmed with TRPC3 channels, while no co-
localization with either the TRPM4 or TRPC6 channels was found[98]. The existence of 
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IP3R co-localization with TRPM4 channels in DSM, but not in arterial myocytes, may 
suggest TRPM4 channel-IP3R spatial interactions follow, to an extent, a certain level of 
tissue-specific expression.  
While our current data provide strong evidence to support the spatial and functional 
coupling of the IP3Rs and TRPM4 channels in human DSM (Fig. 6.3), we cannot exclude 
potential involvement of alternative signaling pathways. IP3 and Ca
2+ are the two central 
modulators of SR IP3R activity[99]. Indeed, IP3R activity has been shown to be regulated 
by IP3 generated downstream from the activation of Gq/11-coupled muscarinic receptor 
pathways involving phospholipase C hydrolysis of phosphatidylinositol bisphosphate 
(PIP2)[99]. Further, more recent studies have shown Ca
2+-permeable TRPC6 channels are 
spatially and functionally coupled with the SR IP3Rs in cerebral arterial myocytes[100]. 
Thus, TRPC6 activation of the IP3Rs lead to Ca
2+ release events from the SR IP3Rs, which 
then activate adjacent TRPM4 channels at the cell membrane[100]. Also, in the 
vasculature, protein kinase C was shown to modulate vascular myogenic tone in a TRPM4 
channel-dependent manner[101, 102]. Consistently, in a separate study on HEK cells 
expressing cloned TRPM4 channels, the sensitivity for TRPM4 channels to Ca2+-
dependent activation is enhanced by PKC phosphorylation[103]. Whether these potential 
TRPM4 channel regulatory mechanisms exist in human DSM is yet to be explored. 
However, as our data confirm IP3R-TRPM4 channel functional coupling, this work 
represents a foundational study in the human urinary bladder and provides a solid platform 
for subsequent mechanistic studies in human DSM (Fig. 6.3).  
The key functional role of the TRPM4 channels in promoting DSM excitability has 
provided an intriguing opportunity for potential therapeutic exploitation in the context of 
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overactive bladder syndrome. Specifically, pharmacological modulators of the TRPM4 
channels or mechanisms controlling their activity may represent a promising novel 
approach for treatment of bladder dysfunction. Given the critical role of the TRPM4 
channels in human DSM function and dysfunction, further efforts to ascertain TRPM4 
channel regulatory mechanisms are critical for confirming and validating their potential 
therapeutic utility. The current study has provided novel mechanistic insight into TRPM4 
channel regulation by SR IP3Rs in human DSM. As current treatments for overactive 
bladder lack efficacy, research efforts to identify novel therapeutic modalities are urgently 
needed and examining TRPM4 channel physiologic roles and mechanisms of regulation is 




Figure 6.1. TRPM4 channels are colocalized with the IP3R of the sarcoplasmic 
reticulum in freshly-isolated human DSM cells. A) Representative image of a human 
DSM cell stained with the anti-TRPM4 goat polyclonal antibody and anti-IP3R rabbit 
polyclonal antibody. As demonstrated in the merge panel in A, the orthogonal cross-section 
image of the human DSM cell is shown in the rectangular box and represents the cross-
sectional plane as indicated by the white dashed line. B) Representative image of a human 
DSM cells stained with only the anti-IP3R rabbit polyclonal antibody (negative control, no 
signal detected). C) Representative image of a human DSM cell stained with the anti-
TRPM4 goat polyclonal antibody and the anti-KV7.5 rabbit polyclonal antibody (negative 
control, no signal detected). As shown in A, positive co-localization of anti-TRPM4 and 
anti-IP3R antibodies is exemplified by red fluorescent staining Results were confirmed in 




Figure 6.2. IP3R inhibition with xestospongin-C decreased TICC activity in human 
DSM cells. A) An original recording showing the inhibitory effect of xestospongin-C (1 
µM) on TICCs in a human DSM single cell recorded at a holding potential of -70 mV. B) 
Summary data illustrating the inhibitory effects of xestospongin-C (1 µM) on TICCs, 
analyzed as single channel open probability (NPo) (n=6, N=4; *P<0.05).  
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Figure 6.3. Illustration of the IP3R regulatory role of TRPM4 channels in human 
DSM function. TRPM4 channels conduct monovalent cations and control human DSM 
membrane potential. TRPM4 channels are controlled by IP3R-mediated Ca
2+ release from 
the sarcoplasmic reticulum as inhibition of the IP3Rs with xestospongin-C reduces TRPM4 
channel activity. Pharmacological blockade of TRPM4 channels with 9-phenanthrol 
hyperpolarizes the DSM cell membrane, inhibits the Ca2+ channels, reduces intracellular 
Ca2+ levels and promotes DSM relaxation[78]. 
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CHAPTER 7
9REGULATION OF GUINEA PIG DETRUSOR SMOOTH MUSCLE 
EXCITABILITY BY 17Β-ESTRADIOL: THE ROLE OF THE LARGE 
CONDUCTANCE VOLTAGE- AND CA2+-ACTIVATED K+ CHANNELS 
ABSTRACT 
Estrogen replacement therapies have been suggested to be beneficial in alleviating 
symptoms of overactive bladder. However, the precise regulatory mechanisms of estrogen 
in urinary bladder smooth muscle (UBSM) at the cellular level remain unknown. Large 
conductance voltage- and Ca2+-activated K+ (BK) channels, which are key regulators of 
UBSM function, are suggested to be non-genomic targets of estrogens. This study provides 
an electrophysiological investigation into the role of UBSM BK channels as direct targets 
for 17β-estradiol, the principle estrogen in human circulation. Single BK channel 
recordings on inside-out excised membrane patches and perforated whole cell patch-clamp 
were applied in combination with the BK channel selective inhibitor paxilline to elucidate 
the mechanism of regulation of BK channel activity by 17β-estradiol in freshly-isolated 
guinea pig UBSM cells. 17β-Estradiol (100 nM) significantly increased the amplitude of 
depolarization-induced whole cell steady-state BK currents and the frequency of 
spontaneous transient BK currents in freshly-isolated UBSM cells. The increase in whole 
cell BK currents by 17β-estradiol was eliminated upon blocking BK channels with 
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paxilline. 17β-Estradiol (100 nM) significantly increased (~3-fold) the single BK channel 
open probability, indicating direct 17β-estradiol-BK channel interactions. 17β-Estradiol 
(100 nM) caused a significant hyperpolarization of the membrane potential of UBSM cells, 
and this hyperpolarization was reversed by blocking the BK channels with paxilline. 17β-
Estradiol (100 nM) had no effects on L-type voltage-gated Ca2+ channel currents recorded 
under perforated patch-clamp conditions. This study reveals a new regulatory mechanism 
in the urinary bladder whereby BK channels are directly activated by 17β-estradiol to 
reduce UBSM cell excitability. 
Abbreviations: BK channels, large conductance voltage- and Ca2+-activated K+ channels; 
CaV channels, L-type voltage-gated Ca
2+ channels; DMSO, dimethyl sulfoxide; UBSM, 
urinary bladder smooth muscle; EGTA, ethylene glycol-bis(2-aminoethylether)-
N,N,N',N'-tetraacetic acid; HEPES, 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid; 
Po, single channel open probability; NPo, single channel total open probability of each 
excised patch; OAB, overactive bladder; RyRs, ryanodine receptors; SR, sarcoplasmic 
reticulum; TBKCs, transient BK currents 
INTRODUCTION 
The functions of the urinary bladder, which are to store and periodically release 
urine, are facilitated by the contraction and relaxation of urinary bladder smooth muscle 
(UBSM). Overactive bladder (OAB), a highly prevalent chronic health condition in the 
United States, is often associated with increased UBSM contractility. The primary 
treatment for OAB involves antimuscarinic agents, which have limited efficacy and 
tolerability [12]. Many forms of OAB have been linked directly to UBSM dysfunction [12, 
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105]. Therefore, novel therapeutic modalities for OAB, targeting UBSM directly, are 
urgently needed. 
Sharing a common embryonic origin, the genital and lower urinary tract systems 
are both regulated by sex hormones, including estrogens [106, 107]. Systemic and vaginal 
estrogen therapies have been considered beneficial in alleviating symptoms of OAB in 
postmenopausal women [106, 107]. Epidemiological studies have also linked post-
menopausal estrogen deficiencies with the increased risk for OAB [106]. Despite these 
observations, conflicting evidence in the literature exists concerning the role of estrogen as 
a treatment for OAB [106]. Some studies suggest beneficial effects of estrogen replacement 
therapies for controlling symptoms of OAB, while other studies report the opposite [106-
108]. Thus, there remains the need for an improved understanding of the mechanisms by 
which estrogens regulate UBSM function [108]. 
The predominant estrogen in human circulation is 17β-estradiol, a potent hormone 
known to regulate urinary bladder function [106, 107, 109, 110]. 17β-Estradiol-induced 
UBSM relaxation has long been established in vitro [111-113] and in vivo [114]. The 
cellular mechanisms of these functional effects of 17β-estradiol in UBSM are not well 
understood, but several mechanisms have been suggested, including L-type voltage-gated 
Ca2+ (CaV) channel inhibition [105, 112] and K
+ channel activation [115]. Among the K+ 
channel targets of 17β-estradiol are the large conductance voltage- and Ca2+-activated K+ 
(BK) channels [116-119]. A previous study in guinea pigs [115] suggested the possible 
involvement of the BK channels in 17β-estradiol-induced UBSM relaxation as the relaxant 
effects of 17β-estradiol were concentration-dependently blocked by the specific BK 
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channel inhibitor iberiotoxin. However, the role of the BK channels as targets for 17β-
estradiol has never been investigated at the cellular level in UBSM.  
BK channels are among the most physiologically-relevant K+ channels regulating 
UBSM excitability and contractility [4, 11]. As both a Ca2+ and voltage sensor, BK 
channels work to oppose UBSM excitability by promoting cell membrane 
hyperpolarization, which in turn precludes Ca2+ influx through L-type CaV channels to 
promote UBSM relaxation [4, 11]. In UBSM, BK channels are activated by either Ca2+ 
influx through L-type CaV channels or by Ca
2+ released from the sarcoplasmic reticulum 
(SR) ryanodine receptors (RyRs), known as “Ca2+ sparks” [11]. BK channel activation by 
Ca2+ sparks triggers transient BK currents (TBKCs), also known as spontaneous transient 
outward currents (STOCs) [11], which regulate UBSM excitability. Given the key role of 
the BK channels in UBSM function [4, 11], their potential regulation by 17β-estradiol 
represents a critically important mechanism in UBSM cell physiology. Indeed, an earlier 
study proposed a potential role for the BK channels in 17β-estradiol-mediated UBSM 
relaxation [115]. However, in UBSM, the existence of a 17β-estradiol-BK channel 
functional interaction has not been investigated at the cellular level. Therefore, this study 
aimed to elucidate the functional role of the BK channels as non-genomic targets of 17β-
estradiol in guinea pig UBSM cell excitability. We employed multiple electrophysiological 
protocols including single BK channel recordings on inside-out excised membrane patches 
and the amphotericin-B perforated whole cell patch-clamp technique in combination with 
the selective BK channel inhibitor paxilline. 
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MATERIALS AND METHODS 
UBSM tissue acquisition and single cell isolation. All experimental procedures were 
conducted in accordance with the animal use protocol #2186 reviewed and approved by 
the Institutional Animal Care and Use Committee (IACUC) of the University of South 
Carolina. Only male animals were used in this study to avoid changes in the estrogen levels 
that occur during the menstrual cycle of the females. Forty-six adult male Hartley-Albino 
guinea pigs (Charles River Laboratories, Raleigh, NC) of average weight 740±177 g were 
euthanized by CO2 inhalation using a SMARTBOX™ automated CO2 delivery system 
(Euthanex Corp, Palmer, PA) followed by thoracotomy. Subsequently, the urinary bladder 
was removed after a transverse incision superior to the bladder neck. Dissection of UBSM 
tissues was performed as previously described [120]. UBSM single cells were isolated from 
UBSM tissues by enzymatic digestion using a combination of collagenase and papain as 
previously described [120]. Freshly-isolated UBSM cells were used for patch-clamp 
experiments within 12 h of isolation. 
Patch-clamp electrophysiology. UBSM cell suspension (0.3-0.5 ml) was placed in a 
glass-bottom chamber to settle for at least 20-30 min. We applied the amphotericin-B 
perforated whole cell patch-clamp technique as previously described [120] to record 
voltage-step depolarization-induced whole cell BK currents, TBKCs, L-type CaV currents, 
and the resting membrane potential of freshly-isolated guinea pig UBSM cells. To 
determine the effects of 17β-estradiol on whole cell steady-state BK currents, UBSM cells 
were voltage-clamped at a holding potential of -70 mV. Subsequently, voltage-step 
depolarizations were applied from -40 to +80 mV at 20 mV intervals for 200 ms. 
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Membrane potential recordings were performed in current-clamp mode (I=0) of the patch-
clamp technique. The effects of 17β-estradiol on peak L-type CaV channel  
currents were recorded at 0 mV in voltage-clamp mode of the amphotericin-B perforated 
patch-clamp technique in the presence of paxilline (1 µM). Single BK channel recordings 
were performed on inside-out excised membrane patches as previously described [120]. 
Single BK channel currents were measured at -60 mV with bath and pipette solutions 
containing symmetrical 140 mM KCl and ~300 nM free [Ca2+] (see §Solutions and 
drugs). These experiments were conducted using pCLAMP version 10.2 software 
(Molecular Devices, Sunnyvale, CA) with an Axopatch 200B amplifier (Digidata 1322A). 
Currents were filtered using an eight-pole Bessel filter (model 900CT/9L8L, Frequency 
Devices, Ottawa, IL). Borosilicate glass patch-clamp pipettes (Sutter Instruments, Novato, 
CA) were pulled using a Narishige glass micropipette puller (model PP-830, Narishige 
Group, Tokyo, Japan) and polished with a Microforge (model MF-830, Narishige Group). 
The final pipette resistance was 4-6 MΩ for whole cell patch-clamp and 6-15 MΩ for single 
BK channel recordings. All patch-clamp experiments were conducted at room temperature 
(22-23°C). 
Solutions and drugs. Ca2+-free dissection solution contained (in mM): 80 monosodium 
glutamate; 55 NaCl; 6 KCl; 10 glucose; 10 N-2-hydroxyethylpiperazine-N'-2-
ethanesulphonic acid (HEPES); 2 MgCl2; NaOH was administered to attain pH 7.3. The 
extracellular solution for whole cell patch-clamp experiments had (in mM): 134 NaCl, 6 
KCl, 1 MgCl2, 2 CaCl2, 10 glucose, and 10 HEPES, pH adjusted to 7.4 with NaOH. The 
patch-pipette solution contained (in mM): 110 potassium aspartate; 30 KCl; 10 NaCl; 1 
MgCl2; 10 HEPES; 0.05 ethylene glycol-bis(2-aminoethylether)-N,N,N',N'-tetraacetic acid 
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(EGTA); NaOH was used to adjust the pH to 7.2. Symmetrical K+ solution used for single 
BK channel recordings contained (in mM): 140 KCl, 1.08 MgCl2, 5 EGTA, and 3.16 CaCl2, 
adjusted to pH 7.2 with NaOH. Stock amphotericin-B solution was freshly prepared daily 
in dimethyl sulfoxide (DMSO) and was added to the 
pipette solution (200-300 μg/ml) prior to the experiment. 17β-Estradiol and paxilline were 
purchased from Sigma-Aldrich (St. Louis, MO) and were dissolved in DMSO. The final 
concentration of DMSO in the bath solution did not exceed 0.01%. 
Data analysis and statistics. Single BK channel openings were analyzed over 5-10 min 
intervals before and after the addition of 17β-estradiol (100 nM). The values for single BK 
channel open probability [107] of each excised patch (NPo) were calculated using Clampfit 
10.2 software as previously described [120]. Single BK channel Po for each patch was 
calculated as NPo where N refers to the number of channels in the patch. The effects of 
17β-estradiol on whole cell steady-state BK currents and the cell membrane potential were 
analyzed using Clampfit 10.2 software. The effects of 17β-estradiol on voltage-step 
depolarization-induced whole cell BK currents were analyzed by taking the average value 
of the last 50 ms of each pulse before and after the application of 17β-estradiol (100 nM). 
The effects of 17β-estradiol on the amplitude and frequency of TBKCs were analyzed using 
Minianalysis software (Synaptosoft, Decatur, GA). The threshold of TBKCs was set at 9 
pA, which is equal to three times the single BK channel amplitude at -20 mV. Data are 
presented as the means ± SEM. In the summarized data, “n” indicates the number of UBSM 
cells used and “N” represents the total number of guinea pigs. CorelDraw Graphics Suite 
X3 software (Corel Co., Mountain View, CA) and GraphPad Prism 4.03 software 
(GraphPad Software, Inc., La Jolla, CA) were used for statistical analysis and data 
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illustration. Paired Student’s t-test was used for statistical analysis. P values <0.05 were 
considered statistically significant.  
RESULTS 
17β-Estradiol enhanced whole cell depolarization-induced steady-state K+ currents in 
freshly-isolated UBSM cells. The average whole cell capacitance of all cells used in the 
present study was 29.8±2.2 pF (n=64, N=46). 17β-Estradiol (100 nM) caused a significant 
increase in whole cell steady-state K+ currents (n=11, N=10; P<0.05, Fig. 1A-B). As 
illustrated in Fig. 1A-B, the density of whole cell steady-state K+ currents at +80 mV were 
30.1±14.6 pA/pF for the controls and 35.8±16.0 pA/pF in the presence of 17β-estradiol. 
To determine whether these stimulatory effects were mediated by the BK channels, we 
examined the effects of 17β-estradiol in the presence of the BK channel inhibitor paxilline 
(1 µM). As shown in Fig. 1C-D, when BK channels were blocked with 1 µM paxilline, 
17β-estradiol had no significant effects on the residual whole cell steady-state K+ currents. 
The density of whole cell steady-state K+ currents at +80 mV was 13.5±2.3 pA/pF for the 
controls (paxilline only) and after the application of 17β-estradiol in the continued presence 
of paxilline was 13.4±2.4 pA/pF (n=14, N=12; P>0.05; Fig. 1C-D). These results indicate 
that in UBSM cells, the increase in whole cell steady-state K+ currents by 17β-estradiol is 
mediated by the BK channels  
17β-Estradiol increased the frequency of TBKCs in freshly-isolated UBSM cells. 
TBKCs have a key role in regulating UBSM cell excitability [4, 11]. We sought to elucidate 
the regulation of TBKC activity by 17β-estradiol in UBSM cells. TBKCs were recorded at 
a holding potential of -20 mV. As illustrated in Fig. 2, 17β-estradiol (100 nM) significantly 
increased the frequency of TBKCs from 0.48±0.15 Hz (control) to 0.59±0.18 Hz (n=9, 
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N=9; P<0.05), without effecting TBKC amplitude (n=9, N=9; P>0.05). Collectively, these 
data indicate that 17β-estradiol regulates TBKC activity in UBSM cells. 
17β-Estradiol increased single BK channel Po in UBSM cell excised membrane 
patches. To elucidate if 17β-estradiol has a direct effect on the BK channels, we conducted 
single BK channel recordings on inside-out excised membrane patches. 17β-Estradiol (100 
nM) increased the mean BK channel NPo from the control value of 0.05±0.03 to 0.20±0.07 
(n=13, N=11; P<0.05). Further, as illustrated in Fig. 3, single BK channel opening events 
were completely abolished by 1 µM paxilline in all excised membrane patches. These data 
provide strong support that 17β-estradiol directly and rapidly activates BK channels in 
UBSM cells. 
17β-Estradiol hyperpolarized the resting membrane potential of UBSM cells. Next, 
we aimed to elucidate the BK channel-dependent regulation of the UBSM cell membrane 
potential by 17β-estradiol in UBSM cells. 17β-Estradiol (100 nM) significantly 
hyperpolarized the UBSM cell membrane potential to -25.8±2.3 mV from the control value 
of -22.1±2.4 mV (n=12, N=11; P<0.05; Fig. 4A-B). The BK channel inhibitor paxilline (1 
µM) reversed the hyperpolarizing effects of 17β-estradiol on the UBSM cell membrane 
potential to -22.2±1.9 mV (n=12, N=11; P<0.05; Fig. 4A-B). As shown in Fig. 4C-D, 17β-
estradiol had no effects on the UBSM cell membrane potential when administered in the 
presence of paxilline (1 µM), with the membrane potential of -19.3±6.7 mV in comparison 
to the control (paxilline only) value of -20.0±7.0 mV (n=7, N=7; P>0.05). These data 
support the concept that 17β-estradiol regulates the UBSM cell membrane potential 
through a mechanism involving the modulation of BK channel activity.  
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17β-Estradiol did not inhibit L-type CaV currents in freshly-isolated UBSM cells. In 
guinea pig UBSM cells, the inhibition of L-type CaV currents by 17β-estradiol has been 
reported at micromolar concentrations using the conventional patch-clamp technique 
[112], which does not maintain the native physiological environment of UBSM cells. Thus, 
we sought to determine whether nanomolar concentrations of 17β-estradiol (100 nM) 
modulates L-type CaV channel activity in UBSM cells in the presence of the BK channel 
inhibitor paxilline (1 µM) using the perforated patch-clamp technique. As exemplified by 
Fig. 5, 17β-estradiol (100 nM) had no effect on L-type CaV channel currents. At 0 mV, the 
average inward current density under control conditions was -1.4±0.3 pA/pF and after the 
addition of 100 nM 17β-estradiol was -1.6±0.4 pA/pF (n=5, N=5; P>0.05; Fig. 5). These 
results support the novel concept that under physiological conditions of the perforated 
patch-clamp, nanomolar concentrations of 17β-estradiol do not directly affect L-type CaV 
channel activity.  
DISCUSSION 
The current study provided the first electrophysiological evidence establishing the 
novel regulatory mechanism by which the BK channels are direct targets for 17β-estradiol 
at nanomolar concentrations in guinea pig UBSM cells. Our results demonstrate that 17β-
estradiol: 1) rapidly increases the amplitude of whole cell steady-state BK currents; 2) 
rapidly increases the frequency of TBKCs; 3) rapidly increases single BK channel NPo; 
and 4) hyperpolarizes the UBSM cell membrane potential; and 5) does not directly inhibit 
L-type CaV channel currents at nanomolar concentrations. 17β-Estradiol is most widely 
known for its long-term genomic mechanisms involving gene expression and the 
promotion of female sexual and reproductive health.  
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Figure 7.1 17β-Estradiol increases depolarization-induced whole cell steady-state BK 
currents in freshly-isolated UBSM cells. A) Representative traces from a voltage-clamp 
experiment illustrating that 17β-estradiol (100 nM) increases whole cell steady-state BK 
currents in an isolated UBSM cell. B) The current-voltage relationship curves illustrate the 
17β-estradiol (100 nM)-mediated increase of whole cell steady-state BK currents in 
isolated UBSM cells (n=11, N=10; *P<0.05). C) Representative traces from a voltage-
clamp experiment illustrating the lack of effects of 17β-estradiol (100 nM) on whole cell 
steady-state BK currents in the presence of the BK channel inhibitor paxilline (1 µM). D) 
The current-voltage relationship curves illustrate that 17β-estradiol (100 nM) had no 
significant effects on whole cell steady-state BK currents in the presence of 1 µM paxilline 
(n=14, N=12; P>0.05). 
However, emerging evidence in UBSM and other cell types suggests the existence of 
several non-genomic mechanisms of 17β-estradiol, which may acutely influence cell 
excitability and contractility.  
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Figure 7.2 17β-Estradiol increases the frequency of TBKCs in freshly-isolated UBSM 
cells. A) An original representative recording illustrating the stimulatory effects of 17β-
estradiol (100 nM) on TBKC activity in an isolated UBSM cell. B) Summarized data 
illustrating the increase in TBKC frequency by 17β-estradiol (100 nM) in UBSM cells 
(n=9, N=9; *P<0.05).  
These non-genomic mechanisms include: inhibition of L-type CaV channels [112, 121, 
122], endothelial-dependent release of nitric oxide [123], activation of protein kinases 
[124], and activation of the BK channels [116, 125]. Involvement of the BK channels in 
the mechanism of 17β-estradiol-induced response is supported by studies from non-UBSM 
cell types and recombinant systems expressing BK channels, which indicate the activation 
of BK channels by 17β-estradiol is dependent on their regulatory β1-subunit [108, 116-
119]. The role of the regulatory β1-subunit was also supported by studies from freshly-
isolated murine colonic myocytes, where the increase in BK channel Po by 17β-estradiol 





Figure 7.3. 17β-Estradiol increases single BK channel Po in excised patches from 
freshly-isolated UBSM cells. A) An original representative recording of BK channel 
currents recorded in the inside-out configuration of the patch-clamp technique before and 
after the addition of 100 nM 17β-estradiol in an excised patch from an isolated UBSM cell. 
Single channel activity was completely abolished by 1 µM paxilline. “O” indicates open 
channel state and “C” indicates closed channel state. B) Summarized data for the effects 
of 17β-estradiol (100 nM) on the BK channel NPo (n=13, N=11; *P<0.05). Single BK 
channel recordings were performed at a holding potential of -60 mV.  
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Figure 7.4. 17β-Estradiol hyperpolarized the membrane potential of freshly-isolated 
UBSM cells. A) A representative trace of a membrane potential recording in current-clamp 
mode (I=0) demonstrating the hyperpolarizing effects of 17β-estradiol (100 nM) in an 
isolated UBSM cell. The hyperpolarizing effect of 17β-estradiol (100 nM) was reversed by 
1 µM paxilline. B) Summarized data illustrating the hyperpolarizing effects of 17β-
estradiol on the UBSM cell membrane potential and that 1 µM paxilline reverses the 17β-
estradiol-induced hyperpolarization (n=12, N=11; *P<0.05). C) A representative trace of 
a membrane potential recording in current-clamp mode demonstrating that when the BK 
channels are blocked with 1 µM paxilline, 17β-estradiol (100 nM) did not cause membrane 
hyperpolarization in an isolated UBSM cell. D) Summarized data illustrating that 17β-
estradiol had no effect on the UBSM cell membrane potential in the presence of 1 µM 
paxilline (n=7, N=7; P>0.05).  
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Figure 7.5. 17β-Estradiol does not inhibit L-type CaV channel activity in freshly-
isolated UBSM cells. A) A representative recording of the peak L-type CaV channel 
currents recorded at 0 mV in a freshly-isolated UBSM cell in the absence (control) or 
presence of 17β-estradiol (100 nM). B) Summary data of the current density of L-type CaV 
channel currents in the absence (control) or presence of 100 nM 17β-estradiol (n=5, N=5; 
P>0.05). 
In UBSM, in vitro functional studies have demonstrated the inhibition of rodent 
and pig UBSM contractility by 17β-estradiol [111, 113, 115]. These observations 
correspond to reports in rat UBSM, where 17β-estradiol decreased the amplitude and 
frequency of spontaneous Ca2+ flashes [113]. A previous study showed that 17β-estradiol-
induced inhibition of UBSM contractility was still achieved in the presence of the estrogen 
receptor antagonist ICI-182,780 [113]. This finding supports a non-genomic   
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mechanism for 17β-estradiol in controlling UBSM contractility that is independent of 
estrogen receptor activation. In guinea pig UBSM, it has been suggested that 17β-estradiol 
acts as both an L-type CaV channel inhibitor and K
+ channel activator [115]. It has been 
shown that micromolar concentrations of 17β-estradiol inhibit L-type Ca2+ currents in 
guinea pig UBSM cells [112], while a separate study showed the relaxant effects of 17β-
estradiol on guinea pig UBSM contractility were blocked in a concentration-dependent 
manner by the selective BK channel inhibitor iberiotoxin [115]. As BK and L-type CaV 
channels are functionally coupled [4, 11], it was important to elucidate these pathways at 
the cellular level in UBSM using nanomolar concentrations of 17β-estradiol under 
physiological experimental conditions. 
Our results show that 17β-estradiol increased the amplitude of whole cell steady-
state K+ currents (Fig. 1) consistent with reports in non-UBSM cell types [117, 126]. The 
rapid effects of 17β-estradiol on whole cell K+ currents were blocked by the BK channel 
inhibitor paxilline, suggesting a BK channel-dependent mechanism.  
Directly confirming the 17β-estradiol-BK channel functional interactions, we 
found that 17β-estradiol (100 nM) significantly increased the single BK channel NPo of 
inside-out excised membrane patches of UBSM cells (Fig. 3). These results are in support 
of earlier electrophysiological reports in non-UBSM cell types showing activation of the 
BK channels by 17β-estradiol [116-119, 127]. Our single BK channel recordings were 
performed using symmetrical K+ solutions with fixed Ca2+ concentration and in the absence 
of signaling pathways that may alter BK channel Po. The rapid effects of 17β-estradiol on 
the UBSM BK channels further indicate direct non-genomic mechanisms. Thus, our data 
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provide clear-cut evidence that 17β-estradiol directly activates BK channels in UBSM 
cells. 
In UBSM cells, Ca2+ sparks released from the SR RyRs activate TBKCs, which 
fundamentally regulate UBSM cell excitability [4, 11]. Activation of TBKCs 
hyperpolarizes the UBSM cell membrane potential and decreases Ca2+ influx through L-
type CaV channels [4, 11]. 17β-Estradiol (100 nM) caused a significant increase in the 
frequency of TBKCs (Fig. 2). While we cannot completely exclude the possibility that 
17β-estradiol may regulate BK channel activity indirectly through modulating the SR Ca2+ 
sparks, the current data (Fig. 3) are in support of a non-genomic mechanism involving a 
direct 17β-estradiol-BK channel interaction. Thus, the increase in TBKC frequency could 
be explained by an increase in BK channel NPo by 17β-estradiol, which can thus increase 
the number of single BK channel opening events at -20 mV (Fig. 2). Therefore, 17β-
estradiol increased the number of small BK channel opening events reaching the TBKC 
threshold of 9 pA, (see  Materials and Methods) as a result of direct modulation of BK 
channel NPo while having no statistically significant effect on TBKC amplitude.  
The negative feedback mechanism by which BK channels limit UBSM excitability 
originates from its ability to control the cell membrane potential [11]. 17β-Estradiol (100 
nM) caused a BK channel-dependent cell membrane hyperpolarization in UBSM cells 
(Fig. 4). 17β-Estradiol-mediated hyperpolarization in UBSM cells is consistent with the 
stimulatory effects of 17β-estradiol on TBKCs and whole cell steady-state BK currents. 
Our study is the first to reveal a direct functional role for the BK channels in 
mediating the effects of 17β-estradiol in UBSM at the cellular level. Importantly, the 
effects of 17β-estradiol on BK channel activity in the current study were achieved using a 
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nanomolar concentration, well below the micromolar concentrations previously used in 
UBSM functional 
studies [111-113, 115]. In particular, it was previously reported using the conventional 
patch-clamp technique that 17β-estradiol, at much higher non-physiological micromolar 
concentrations (1 µM), inhibited peak Ca2+ currents by 50% in guinea pig UBSM cells 
[112]. However, 17β-estradiol never reaches micromolar concentrations in the blood 
plasma even under pathophysiological conditions. We demonstrated here for the first time 
using the perforated whole cell patch-clamp technique, that 17β-estradiol (100 nM) had no 
direct effects on L-type CaV channel activity in freshly-isolated guinea pig UBSM cells 
(Fig. 5). These data suggest that 17β-estradiol directly activates the BK channels at 
nanomolar concentrations, which are insufficient to affect L-type CaV channel activity. 
Unlike our study, previous studies that showed L-type CaV channel inhibition by 17β-
estradiol in guinea pig UBSM cells have used physiologically-irrelevant high micromolar 
concentrations [112]. Thus, our study reveals the novel findings that L-type CaV channel 
inhibition by 17β-estradiol is not involved in UBSM relaxation under normal physiological 
conditions.  
The current study provides strong evidence supporting a role for the BK channels 
as low-affinity non-genomic targets for 17β-estradiol in UBSM. Our study does not 
exclude the possibility that 17β-estradiol may exert genomic effects on the BK channels 
directly through estrogen receptor stimulation. However, the rapid increase in single BK 
channel NPo by 17β-estradiol (Fig. 3) clearly indicates that the BK channels are direct non-
genomic targets for 17β-estradiol. As the role of estrogens in UBSM physiology and 
pathophysiology is not fully understood, the current study provides a foundational basis 
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for future studies in human UBSM. Indeed, decreased estrogen levels have been associated 
with the increased occurrence of urinary urgency and frequency in post-menopausal 
women [106-108, 128]. Thus, the activation of the BK channels by 17β-estradiol, which in 
turn hyperpolarizes the membrane potential to cause UBSM relaxation, may underlie some 
of the observed benefits of estrogen replacement therapies in alleviating symptoms of OAB 
[108].In conclusion, we reveal a new paradigm in UBSM cell physiology, indicating a 
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